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Visual memory is a complex neurophysiological process wherein visual inputs are transduced 
and encoded within networks of synapsing neurons. At the core of this system are 
neurotransmitters and postsynaptic receptors, including N-methyl-D-aspartate (NMDA) receptors, 
which are necessary for visual memory in mice. Interestingly, with age there is a predictable, visual 
experience-dependent replacement of NMDA receptor subunit NR2B by a second subunit, NR2A. 
Both subunits have been implicated in regulating potentiation in the murine primary visual cortex 
(V1) in response to visual stimulus in other forms of plasticity, such as ocular dominance. The 
goal of this project was to characterize NMDA receptor subunit composition changes during the 
acquisition of visual memory and to elucidate the role of NR2B in stimulus-specific response 
potentiation (SRP) and orientation-selective habituation (OSH), which are electrophysiological 
and behavioral manifestations of visual memory, respectively. To this end, we measured NR2A 
and NR2B protein levels via Western blot in mice before and after six days of exposure to a 
sinusoidal grating stimulus. We also evaluated SRP and OSH in mice in which NR2B was 
selectively deleted by Cre recombinase or pharmacologically inhibited by either CP-101,606 or 
Ro 25-6981. Our preliminary findings indicate that NMDA subunit exchange in V1 is minimal 
during the acquisition of visual memory. We observed that the loss of NR2B does not appear to 
impact SRP or OSH, suggesting that the subunit does not play a role in visual memory, although 
these biological effects are obscured by high variance and small sample sizes. Finally, we report 
that DMSO—used as a pharmacological vehicle—may inhibit the acquisition, but not the 
consolidation of visual memory. Our work here on characterising NMDA receptor subunit NR2B 
explores one aspect of the biochemical basis of plasticity in V1 and suggests alternative 
mechanisms that underlie visual memory that warrant further investigation in order to fully 




“Memory in youth is active and easily impressible; in old age it is comparatively callous to new 
impressions, but still retains vividly those of earlier years.” (Charlotte Brontë) 
 
Writing from the 1840s, Charlotte Brontë reflected on memory and its intimate relationship 
with age. Today, memory is recognized as a beautifully intricate process, involving the cross-talk 
of complex neural networks and biomolecular signaling events, that underlies human cognition. 
Environmental cues—sight, sound, touch, smell, and taste—are integrated and recorded into 
memory for retrieval at a later time. For simplicity, this volume will specifically focus on visual 
memory, its biochemical basis, and its physiological manifestations. 
It would be remiss to begin this discussion without recognizing that animals learn from their 
sensory environment. During the 1940s, for instance, Donald O. Hebb remarked that rodents kept 
as pets seemingly outperformed their counterparts raised in cages on problem solving tests, 
suggesting that stimuli in the environment could shape behaviors independently of artificial 
learning, including Pavlovian conditioning (Hebb, 1947). Then, in the 1960s David Hubel and 
Torsten Wiesel observed that monocular deprivation, or the intentional disruption of sight through 
one eye in binocular animals, led to cellular and anatomical changes within the brain (Wiesel and 
Hubel, 1963). Specifically, following monocular deprivation, groups of neurons found within the 
primary visual cortex (V1) that typically receive visual input from one or both eyes, termed ocular 
dominance columns, only received input from a single eye; ocular dominance columns that 
received input from the open eye were enlarged in V1 and expanded into space within the cortex 
normally occupied by ocular dominance columns corresponding to the contralateral eye (Wiesel 
and Hubel, 1963). Taken together, these observations suggest that environmental stimuli can shape 
the brain and impact cortical function. 
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2.2 Long-term Potentiation in the Murine Visual Cortex 
In neuroscience, it is widely accepted that patterned stimulation of the brain can strengthen the 
synapses activated by the stimulus, in a process termed long-term potentiation (LTP) (Bliss and 
Lomo, 1973). The inverse process, long-term depression (LTD), or the progressive weakening of 
synapses can also occur, typically following lower-frequency stimulation. These two opposing 
processes are thought to form the basis of learning and memory, and contribute to synaptic 
plasticity, or the ability of neurons to alter the strengths of their chemical synapses. LTP has been 
observed in many sensory modalities across several species, including humans (Fahle and Morgan, 
1996; Furmanski et al., 2004; Gilbert et al., 2001; Karni and Bertini, 1997; Poggio et al., 1992). 
Notably, plasticity changes in the form of electrophysiological signals in V1 have been observed 
in mice exposed to familiar visual stimuli that resemble canonical presentations of LTP (Cooke 
and Bear, 2010; Frenkel et al., 2006). V1 is a bilaterally paired region of the cortex in the occipital 
lobes that receives visual input from the eyes via the optic nerves and dorsal lateral geniculate 
nucleus (dLGN) of the thalamus. Interestingly, it has been demonstrated in later work that LTP in 
V1 occurs independently of structures traditionally associated with memory, including the 
hippocampus. Indeed, pharmacological hippocampal ablation does not affect the ability of V1 to 
undergo an LTP-like process in response to visual stimuli (unpublished work). This observation 
suggests that neural networks within V1 are capable of undergoing plasticity changes in response 
to visual stimuli, which might underlie familiarization, habituation, and object recognition.  
2.3 Stimulus-specific Response Potentiation (SRP) 
Electrical activity in the brain has been correlated with specific stimuli and cognitive processes. 
Visual recognition is no exception. In mice, recognition of familiar visual stimuli has been reported 
to manifest electrophysiologically as the progressive increase in cortical activity in V1, a 
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phenomenon dubbed stimulus-specific response potentiation (SRP) first observed incidentally in 
mice (Frenkel et al., 2006; Sawtell et al., 2003). In this paradigm, repeated exposure to the same 
phase-reversing, sinusoidal grating visual stimulus (a series of lines presented at a fixed angle) 
elicits a predictable increase in the overall amplitude of visually evoked potentials (VEPs), which 
measure the strength of cortical responses (Fig. 1). VEPs are obtained by measuring electrical 
activity in mice in response to visual stimuli via implanted electrodes, and VEP magnitudes are 
calculated by averaging the trough-peak amplitudes of VEP waveforms. For instance, over a five-
day period, the mean amplitude of VEPs have been reported to double (261.1 µV on day one 














Figure 1: Repeated exposure to familiar phase-reversing, sinusoidal grating visual stimulus 
visual stimulus increases the magnitude of visually evoked potentials (VEP) measured in 
layer 4 of V1. (A) Head-fixed mice were exposed to the same stimulus for eight days. On day 9, 
mice were either shown a familiar stimulus (outlined in blue) or a novel stimulus (outlined in red). 
(B) VEP magnitudes, which were recorded on each day while mice were exposed to the familiar 
stimulus, increased with repeated exposure. Bars represent averaged amplitudes from VEP 
waveforms obtained from mice (n = 19). Average VEP waveforms are also provided above the 
graph. Vertical scale bar represents 50 µV; horizontal scale bar represents 100 ms. (C) VEP 
magnitudes decrease when mice are exposed to novel stimulus orientation on day 9 relative to VEP 
magnitudes measured on day 8 (red), while VEP magnitudes continue to increase when mice are 
exposed to familiar stimuli on day 9 (blue). Bars represent averaged amplitudes from VEP 
waveforms obtained from mice (n = 19). Circles represent VEP magnitudes measured in individual 
mice shown familiar (blue) and novel (red) stimuli, while lines represent the change in VEP 
magnitude between conditions. Figure adapted from Cooke et al. (2015).  
A B C 
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Strikingly, exposure to a novel stimulus orientation elicits VEPs of smaller amplitude, relative 
to the familiar orientation. Indeed, even subtle differences in the presented visual stimulus have 
been shown to reduce the amplitude of VEPs, suggesting that at a neurophysiological level, mice 
are able to recognize and distinguish between similarly oriented visual stimuli. To illustrate this 
specificity, lines that deviate from familiar by as little as 5˚ elicit significantly smaller VEP 
amplitudes. Taken together, these observations support the notion that synaptic potentiation in 
response to repeated exposure to familiar stimuli is highly specific and can be observed via SRP 
(Cooke and Bear, 2010; Frenkel et al., 2006).  
In addition to its selectivity to stimuli, SRP has been shown to be specific to the eye viewing 
the stimulus. Monocular exposure to a stimulus elicited SRP in the trained, but not the untrained 
eye (Frenkel et al., 2006), suggesting that changes in plasticity are largely driven by a small number 
of neurons that respond exclusively to visual signals from the trained eye. It is worth noting that 
SRP is not confined to the early postnatal critical period, after which plasticity is diminished and 
neural circuitry underlying visual memory is cemented (Frenkel et al., 2006). Indeed, progressive 
enhancements in VEP amplitudes can still be observed in adult mice beyond the traditional ocular 
dominance “critical period” (Frenkel et al., 2006). 
Given that SRP co-occurs with local plasticity changes in response to visual stimuli, it has been 
suggested that SRP is a manifestation of LTP. Two lines of evidence support this position: (1) the 
induction of thalamocortical LTP (including V1) by theta burst electrical stimulation (TBS), which 
involves repetitive magnetic pulses that elicit changes in electrical activity, in the dLGN both 
mimics and occludes SRP (and vice versa). Stated otherwise, changes to VEP magnitudes 
following TBS resemble those seen in mice that have undergone SRP. Moreover, mice treated 
with TBS are unable to undergo SRP when shown the same stimulus as during TBS, suggesting 
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that LTP and SRP share similar biological processes. (2) Disrupting the maintenance of LTP via 
zeta-inhibitory peptide (ZIP) interference of calcium-dependent kinase PKMz, which is necessary 
for LTP, reduces VEP amplitudes in V1 after prior induction of SRP (Cooke and Bear, 2010). 
These findings suggest that LTP in V1 and its associated neurophysiological changes in response 
to familiar visual stimulus lead to the appearance of SRP. Therefore, SRP could provide a 
convenient in vivo assay of LTP in mice exposed to visual stimulation. 
2.4 Orientation-selective habituation (OSH) 
In addition to SRP, which provides an electrophysiological readout for visual recognition, a 
second phenomenon called orientation-selective habituation (OSH) has been reported to emerge 
in parallel (Cooke et al., 2015). When exposed to visual stimuli, mice exhibit a distinct fidgeting 
behavior, dubbed the “vidget,” that decreases in magnitude with familiarity to a given stimulus 
(Fig. 2). Indeed, when mice are exposed to the same phase-reversing, sinusoidal grating visual 
stimulus, the average magnitude of vidgets, accessed via piezoelectric sensor placed under the 
forepaws, fell by over 64% across eight days. When trained mice were exposed to a novel visual 
stimulus on the ninth day, the magnitude of vidgets increased by almost 100% relative to the 
magnitude of vidgets observed during the previous day, suggesting that the behavioural response 
is specific to a given visual stimulus (Cooke et al., 2015). These observations mirror those observed 
in SRP, where the amplitude of VEPs increases with familiarity to a given visual stimulus (Cooke 



















Figure 2: Repeated exposure to familiar phase-reversing, sinusoidal grating visual stimulus 
decreases the magnitude of visually evoked fidget behaviors (vidgets). (A) Head-fixed mice 
were exposed to the same stimulus for eight days. On day 9, mice were shown both a familiar 
stimulus (outlined in blue) and a novel stimulus (outlined in red). (B) Vidget magnitudes, which 
were recorded each day while mice were exposed to the familiar stimulus, decrease with repeated 
exposure. Bars represent averaged amplitudes from piezoelectrical signals obtained from vidgets 
in mice (n = 19). Average vidget waveforms are also provided above the graph. Vertical scale bar 
represents 1 a.u.; horizontal scale bar represents 5 s. (C) Vidget magnitudes increase when mice 
are exposed to novel stimuli on day 9 (red) relative to vidget magnitudes measured on day 8, while 
vidget magnitudes remain relatively stable when exposed to familiar stimuli on day 9 (blue). Bars 
represent averaged amplitudes from vidget waveforms obtained from mice (n = 19). Circles 
represent vidget magnitudes measured in individual mice shown familiar (blue) and novel (red) 
stimuli, while lines represent the change in vidget magnitude between conditions. Figure adapted 
from Cooke et al. (2015). 
 
Like SRP, OSH is eye-specific, supporting the notion that neural circuits modified by visual 
input are not shared downstream of segregated monocular projections from dLGN (Cooke et al., 
2015). In the case of OSH, when each eye is habituated with a differently oriented stimulus and 
subsequently exposed to the contralateral stimulus, vidget magnitudes increase in each eye, 
suggesting that the neural circuitry that receives input from each eye recognizes this new stimulus 
as novel. In the case of SRP, following exposure to the contralateral stimulus, VEP magnitudes 
decrease in each eye, corroborating observations above (Cooke et al., 2015). 
As SRP and OSH occur simultaneously during habituation, OSH is thought to be a behavioral 
manifestation of the LTP-like process in V1. The elimination of LTP by ZIP peptide, which was 
A B C 
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previously shown to preclude SRP, similarly abolishes OSH in mice, supporting the hypothesis 
that this visually-evoked form of LTP manifests electrophysiologically as SRP and behaviorally 
as OSH (Cooke et al., 2015). Consistent with this finding, unlike many other non-stimulus-specific 
reflexive behaviors, OSH depends on neuronal activity within V1. Treatment of V1 with GABAA 
receptor agonist muscimol, which reduces neuronal activity by hyperpolarizing the neuron, thereby 
inhibiting the formation and propagation of action potentials, reduced both the magnitude of VEP 
amplitudes and the magnitude of vidgets in mice exposed to familiar stimuli (Cooke et al., 2015). 
The same result was observed in mice in which V1 signalling was perturbed by the local activation 
of channelrhodopsin-2 in parvalbumin-expressing GABAergic interneurons, which activate these 
inhibitory neurons, thereby suppressing neural activity, supporting the notion that SRP and OSH 
are driven by neuronal circuits located within V1 (Cooke et al., 2015). Taken together, these results 
demonstrate that SRP and OSH might arise from the occurrence of LTP in V1 in response to 
habituation to visual stimuli. 
2.5 Role of NMDA Receptors in Memory 
At the basis of the neuronal networks that permit memory formation are neurotransmitters, 
which primarily transmit neuronal impulses from presynaptic neurons to postsynaptic neurons. 
The amino acid glutamate is a neurotransmitter that binds to glutamatergic receptors including N-
methyl-D-aspartate (NMDA) receptors on the postsynaptic membrane (McBain and Mayer, 1994). 
A large volume of literature has implicated the activity of NMDA receptors in initiating synaptic 
plasticity and the reorganization of neuronal circuits involved in learning and memory in the CNS. 
As with other ionotropic receptors, NMDA receptors are ligand-gated ion channels activated by 
glutamate and glycine, permitting the passive movement of non-specific cations through the 
channel (Fig. 3). Though the movement of cations, including sodium, calcium, and potassium, 
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through the channel requires ligand binding, net flux is ultimately dependent on membrane 
potential, which contributes to the chemiosmotic gradient and regulates the binding of magnesium 
ions to specific sites within the channel. These magnesium ions effectively block the flow of other 
cations unless they are displaced by membrane depolarization (McBain and Mayer, 1994). 
Generally, the activation of NMDA receptors results in the net flow of positively charged sodium 


















Figure 3: Schematic representation of NMDA receptor activation by co-agonists glycine and 
glutamate. NMDA receptor is an ionotropic ligand-gated cation channel that is activated by the 
binding of glycine (orange) to subunit NR1 (labeled GluN1 above) and glutamate (turquoise) to 
subunit NR2 (labeled GluN2). Magnesium ions (yellow) also bind to subunit NR2 and prevent the 
movement of sodium (blue), calcium (maroon), and potassium (green) ions across the neuronal 
membrane. Displacement of magnesium ions by membrane depolarization (not shown) permits 
the net flow of positive ions into the cell along their chemiosmotic gradient. Figure adapted from 
Balu (2016). 
 
Structurally, NMDA receptors are heteromeric transmembrane proteins composed of four 
peptide subunits (Fig. 4A), including two obligatory NR1 subunits and two variable NR2 or NR3 
subunits. Among each type of subunit, different subtypes also exist (e.g., NR2A-D encoded by 
four different genes, NR1-1a/b-NR1-4a/b formed by alternative splicing of the GRIN1 mRNA), 
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contributing to the overall diversity of NMDA receptors in the brain (McBain and Mayer, 1994). 
On the whole, the different subunits share similar structural elements: an extracellular N-terminus 
and four transmembrane domains. NMDA receptor subunits tend to vary in amino acid sequence 
within the intracellular C-terminus, which has been shown to be important in interacting with 
intracellular proteins, including protein kinases and phosphatases (Fig. 4B) (McBain and Mayer, 
1994). NR1 subunits (approximately 920 amino acid residues, 103.4 kDa) are known to bind 
glycine, while NR2 subunits have been shown to bind glutamate and contribute to interactions 
with magnesium ions (Fig. 3). Consistent with these observations, it has been posited that NR2 
subunits are largely responsible for regulating the electrochemical properties of NMDA receptors 
(McBain and Mayer, 1994). In the context of V1 plasticity changes, two NR2 subtypes—NR2A 
(1442 amino acid residues, 162.8 kDa) and NR2B (1456 amino acid residues, 163.2 kDa)—are 
most commonly discussed since they are the most abundant subunits in the mammalian forebrain 



















Figure 4: The structure of NMDA receptors. (A) A ribbon structure of the heterotetrameric 
NMDA receptor containing two subunits of NR1 (blue) and two subunits of NR2 (orange). (b) 
Comparison between amino acid sequences of NR1 (labeled NMDAR1), NR2A, and NR2B. Note 
the number and location of transmembrane domains (black boxes labeled as TM1-3, TM4) and the 
length of the peptides. SP: signal peptide. Figures adapted from (a) Hansen et al. (2018) and (B) 
McBain & Mayer (1994). 
 
As in other regions of the brain, NMDA receptors have been demonstrated to be necessary for 
SRP in V1. For instance, pharmacological inhibition of NMDA receptor by antagonist 3-(2-
carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) has been demonstrated to abolish SRP and 
therefore, LTP, in mice (Frenkel et al., 2006). Moreover, the targeted deletion of obligatory 




that the activity of NMDA receptors is necessary for the manifestation of electrophysiological 
changes associated with LTP. These findings are consistent with prior observations of the role of 
NMDA receptors in ocular dominance plasticity in mice (Sawtell et al., 2003). Classically, 
binocular regions of V1 receive signals largely from the contralateral eye with a minor contribution 
from the ipsilateral eye. Monocular deprivation of the contralateral eye strengthens visual input 
from the ipsilateral eye via a process dependent on the activation of NMDA receptors (Sawtell et 
al., 2003). Indeed, changes to ocular dominance plasticity are abolished in mice containing targeted 
NR1 subunit deletions, suggesting a possible role of NMDA receptors in reorganizing neuronal 
circuits following changes to visual stimulus input (Sawtell et al., 2003).  
Consistent with the findings described previously, the activity of NMDA receptors in V1 is 
also required for OSH, the behavioral manifestation of LTP in V1 (Cooke et al., 2015). Targeted 
deletion of NMDA receptor subunit NR1 in V1 abolishes OSH and prevents mutant mice from 
distinguishing between familiar and novel stimuli (Cooke et al., 2015). Similarly, the inhibition of 
NMDA receptors in V1 via localized delivery of antagonist 2-amino-5-phosphonopentanoate 
(AP5) prevented the acquisition of OSH and SRP in mice prior to exposure to visual stimuli (Cooke 
et al., 2015). Taken together, these observations support the notion that NMDA receptors are 
required for the establishment and maintenance of OSH, SRP, and therefore, LTP in V1.  
In addition to the demonstrated role of NMDA receptor activity in V1 that underlies LTP and 
complex processes related to visual memory formation and maintenance, NMDA receptors 
undergo a predictable biochemical change during the life time of vertebrates. Indeed, during 
prenatal and early post-natal developmental periods (first five weeks in mice), NMDA receptors 
in the forebrain contain primarily NR2B subunits, while NMDA receptors in the brain during late 
post-natal developmental periods corresponding to the end of juvenile plasticity contain relatively 
 17 
more NR2A subunits (Fig. 5A), suggesting that the gradual replacement of NR2B subunits by 
NR2A subunits is a normal physiologic process related to the development and aging of mammals, 
including mice (Cho et al., 2009; Quinlan et al., 1999). It must be noted that cells do not actively 
exchange NR2A subunits for NR2B subunits in existing NMDA receptors on the postsynaptic 
membrane. Prior work has shown that NMDA receptors localized in newly established cortical 
and thalamic synapses contain a mixture of NR2B and NR2A, suggesting that NR2A may be 
preferentially expressed following the formation of new connections in response to novel learning 
(Liu et al., 2004). This finding is supported by the observation that the developmental NMDA 
receptor subunit exchange is abolished in dark-reared animals (i.e., lacking visual input) (Quinlan 
et al., 1999). Moreover, exposure to light (and the surrounding visual environment) causes a rapid 
increase in NR2A subunit composition in V1, suggesting that the transition from NR2B to NR2A 
is experience-dependent and likely underlies alterations to the electrochemical properties of 














Figure 5: Experience-dependent subunit exchange alters the composition and 
electrochemical properties of NMDA receptors. (A) A schematic representation of the NR2B-
to-NR2A transition with increasing visual stimulation and age. (B) The presence of NR2A causes 
NMDA receptors to generate more rapid excitatory post-synaptic currents (smaller offset decay 
time constant, t) compared to NR2B-containing NMDA receptors. Figure (B) adapted from 
Monyer et al. (1994). 
  
Before exploring the functional relationship between NMDA receptor subunit composition and 
processes that govern LTP in V1, it is worth contrasting the physical properties of NR2B-
containing NMDA receptors and NR2A-containing NMDA receptors. While NR2B-containing 
NMDA receptors and NR2A-containing NMDA receptors do not differ significantly in terms of 
calcium ion permeability, the offset decay time constant of NR2A-containing NMDA receptors is 
almost three-to-four times smaller than that of NR2B-containing NMDA receptors (Monyer et al., 
1994), suggesting that NR2A-containing NMDA receptors mediate shorter excitatory post-
synaptic currents than NR2B-containing NMDA receptors (Fig. 5B). Stated otherwise, NR2B-
containing receptors remain open for a longer period of time. Consistent with these findings, 
















increasing the NR2B/NR2A subunit ratio in NMDA receptors also increases the duration of 
NMDA receptor excitatory post-synaptic currents (Quinlan et al., 1999). The converse is also true, 
supporting the notion that NMDA receptor subunit composition determines its electrochemical 
properties.  
Interestingly, it has been claimed that the activation of NR2A-containing NMDA receptors is 
necessary for LTP, or synaptic strengthening, while the activation of NR2B-containing NMDA 
receptors, which remain open longer than NR2A-containing NMDA receptors, is necessary for 
LTD, or synaptic weakening (Massey et al., 2004). This hypothesis is consistent with the fact that 
LTP and LTD are both invoked by post-synaptic excitatory currents and calcium influx, with the 
former elicited by higher frequency stimulation and the latter elicited by lower frequencies. The 
threshold between LTP and LTD is defined as the modification threshold, which is thought to shift 
according to NMDA structure. It has been proposed that NMDAR subunit composition controls 
the modification threshold for bidirectional synaptic plasticity, although the evidence of this role 
depends on the nature of experimental manipulations used in each study. For instance, lowering 
the NR2A/NR2B ratio has been shown to reduce the threshold necessary to induce LTP in murine 
V1 (Cho et al., 2009; Philpot et al., 2007). Furthermore, the genetic disruption of NR2A in cortical 
layer 4 of V1 has also been shown to reduce the LTD/LTP threshold, thereby promoting LTP in 
murine V1, in a dosage-dependent manner (Cho et al., 2009). Taken together, these data suggest 
that the experience-dependent shift in NMDA receptor NR2 subunit identity underlies changes in 
V1 cortical plasticity by altering the electrophysiological threshold that determines the stimulation 
properties eliciting LTP versus LTD.  
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2.6 Investigating the involvement of NDMA receptor subunit exchange in SRP 
Given the exquisite role of NMDA receptor subunit exchange in regulating the electrochemical 
properties of NMDA receptor, which have been shown to underlie SRP and OSH, there is great 
interest in understanding how the biochemical changes in NMDA receptor composition occur 
during familiarization with visual stimuli and the acquisition and consolidation of visual memory.  
The goal of this present work is foremost to characterize the NR2B-to-NR2A NMDA receptor 
shift in V1 during SRP induced by repeated exposure to the same visual stimulus via Western blot. 
Since visual deprivation is associated with reduced NR2A/NR2B ratio, we hypothesize that SRP 
is correlated with a rise in NR2A relative to NR2B. 
Moreover, since the NR2B-to-NR2A transition is experience-dependent and correlated with a 
loss of V1 cortical plasticity, this project also aims to determine whether the NR2B-to-NR2A 
transition, specifically, stabilizes SRP during the familiarization of visual stimuli by the targeted 
disruption of NR2B via genetic and/or pharmacological means. Our goal is to understand how SRP 
and OSH change as a result of the deletion of floxed NR2B alleles specifically in V1 excitatory 
cells via Cre-mediated recombination and the selective inhibition of NR2B-containing NMDA 
receptors via NR2B selective antagonists CP-101,606 and Ro 25-6981 (Menniti et al., 1998) in 
mice repeatedly exposed to the same set of visual stimuli. 
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3 Methods & Materials 
3.1  Animal Husbandry 
All procedures involving live mice and mouse tissues were approved by the Committee on 
Animal Care (CAC) at MIT. For NMDA receptor subunit composition and pharmacological 
inhibition experiments, wild-type male and female C57BL/6N mice aged postnatal days 27-29 
(p27-29) were obtained from Charles River Laboratory or bred from existing mouse lines housed 
at the Picower Institute for Learning and Memory Mouse Colony. For NR2B conditional knockout 
experiments, C57BL/6N mice aged p56-66 engineered with homozygous NR2B conditional 
alleles (Grin2bfl/fl) (Sanz-Clemente et al., 2013) were obtained from breeders generously donated 
by Professor Roger A. Nicoll at UCSF.  
3.2 Headpost and Electrode Implantation 
In each experiment, mice were implanted with a headpost to fix head position and standardize 
the viewing angle for visual stimuli. Mice were first anesthetized with 3% isoflurane (chamber) or 
1.5% isoflurane (nosecone). The scalp of each mouse was then shaved, cleaned with betadine and 
70% ethanol, and injected subdermally with 1% lidocaine hydrochloride. Mice were also injected 
with 1 mg/kg meloxicam and 0.1 mg/kg buprenorphine subcutaneously to provide analgesia. A 
small incision was made to the scalp to expose the skull. Following the incision, a steel headpost 
was attached to the skull anterior to the bregma along the sagittal suture using cyanoacrylate glue 
(Loctite® 454). 
For the electrophysiology experiments, mice were also implanted bilaterally with electrodes 
into layer 4 of binocular V1 in order to measure V1 electrical activity. To implant the electrodes 
into V1, burr holes (<0.5 mm) were drilled in the skull over the visual cortex perpendicular to the 
sagittal suture. For the NR2B conditional knockout experiment, burr holes were drilled 3.05 mm 
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lateral to lambda to account for larger brain size in older animals (p56-66). For all other 
experiments, burr holes were drilled 2.95 mm lateral to lambda (p27-29 animals). Tungsten 
electrodes (FHC, 75 µm in diameter) were then inserted bilaterally 450 µm below the surface of 
the cortex. A reference (ground) electrode was also implanted in the right frontal cortex (anterior 
to the coronal suture, right of the sagittal suture) at a depth of ~250-500 µm subdurally. Electrodes 
were affixed using Loctite® 454 superglue, and the headpost and electrodes were covered with 
dental cement. Mice were monitored postoperatively for distress and were allowed to recover for 
3 days. During this recovery period, the mice were injected subcutaneously with 0.1 mg/kg 









Figure 6: Location of headpost and electrode implantation on the skull of mice. The headpost 
(green) was affixed to the skull anterior to the bregma along the sagittal suture, while the ground 
electrode (blue) was implanted anterior to the coronal suture and right of the sagittal suture. 
Electrodes (red) were implanted 2.95-3.05 mm lateral to lambda and perpendicular to the sagittal 
suture. Figure adapted from Paxinos and Watson (1998). 
 
3.3 Viral Injection 
Adeno-associated viruses (AAV8) were used to locally infect CaMKII-expressing cells of the 
visual cortex to knockout NR2B in Grin2bfl/fl mice. These mice were injected with AAV8 












expressing either Cre recombinase and green fluorescent protein (GFP) under the control of the 
promoter of the gene encoding alpha-Ca2+/calmodulin-dependent protein kinase II (CaMKII) 
(NR2B KO; AAV8-CaMKII-Cre-GFP) or GFP alone under the control of the same promoter 
(control; AAV8-CaMKII-GFP); both viruses were obtained from the University of North Carolina 
viral core.  
Viral injections were delivered during the same surgical session as headpost and electrode 
implantation for the NR2B conditional knockout experiment. Viral injections were delivered using 
a glass pipette and Nanoject III system (Drummond Scientific) at three cortical depths below the 
surface of the skull: 250 µm, 450 µm, and 750 µm. Injections were delivered perpendicular to the 
sagittal suture and 2.90 mm from lambda bilaterally. At each depth, 9 injections of 9.6 nL were 
delivered 30 seconds apart at a rate of 46 nL/s (86.4 nL total), and 2 min were allowed between 
repositioning for depth. Mice were monitored postoperatively for distress and were allowed to 
recover for 3 days. During this initial recovery period, the mice were injected subcutaneously with 
0.1 mg/kg buprenorphine 6 hours following injection and 1 mg/kg meloxicam every 24 hours for 
the 3 postoperative days. Mice were then allowed 4 weeks of recovery before further 
experimentation to allow for robust viral expression. 
3.4  Pharmacologic Injection 
Intraperitoneal injections were performed in accordance with CAC and Bear Lab guidelines. 
In one set of pharmacological inhibition experiments, mice were injected intraperitoneally with 
CP-101,606 (10 mg/kg) (Sigma-Aldrich, SML0053) dissolved in 75% v/v DMSO in Milli-Q 
sterile water or vehicle alone. In a second set of pharmacological inhibition experiments, mice 
were injected with Ro 25-6981 (10 mg/kg) (Sigma-Aldrich, SML0495) dissolved in isotonic saline 
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or vehicle alone. Further experimentation commenced either 30 (Ro 25-6981) or 60 (CP-101,606) 
min following injections to allow for drug uptake, diffusion, and binding to NR2B. 
3.5 Recording Rig Design 
To standardize visual stimulus presentation across different mice and stimulation conditions, 
we employed a recoding rig described in Cooke et al. (2015). To immobilize mice and prevent 
changes in viewing perspective, mice were placed into a cylindrical tube and their heads were 
restrained via implanted headpost, respectively. Implanted electrodes used to measure VEPs and 
piezoelectric sensors placed under the forepaws of the mouse to measure vidgets were then 
connected to the recording system (Plexon OmniPlex Recorder-64). Phase reversing grating visual 
stimuli were presented to the head-restrained mouse via a digital display that was placed 20 cm 


















Figure 7: Recording rig to standardize visual stimulus presentation to head-fixed mice. 
Implanted electrodes and piezoelectric sensor placed underneath the forepaws measure to VEP and 





3.6 Stimulus Presentation 
Phase-reversing grating visual stimuli were generated using custom code written in MATLAB 
and C++ by Jeff Gavornik that permitted control of the spatial frequency, angle, contrast, number 
of sets of phase reversals (flip/flops), number of sessions, interstimulus interval, and phase reversal 
frequency of visual stimuli. Prior to all experiments, mice were acclimatized to the recording rig 
by being head-fixed and exposed to grey screen for 30 min per day for 2 days. For NMDA receptor 
subunit composition experiments, mice were presented with 300 s of grey screen before one of 
four different visual stimulation protocols. One group of negative control mice received 5 blocks 
of grey screen stimulus for 6 days. The experimental group were presented with a 2 Hz, 0.05 
cycles/degree, 100% contrast, 45˚ sinusoidal grating visual stimulus over 5 blocks of 100 phase 
reversals with 30 s between blocks and 500 ms between phase reversals for 6 days. Another 
negative control group received 5 days of grey screen stimulus followed by a single day of a 2 Hz, 
0.05 cycles/degree, 100% contrast, 45˚ sinusoidal grating visual stimulus over 5 blocks of 100 
phase reversals with 30 s between blocks and 500 ms between phase reversals. The final negative 
control group received a single day of a 2 Hz, 0.05 cycles/degree, 100% contrast, 45˚ sinusoidal 
grating visual stimulus over 5 blocks of 100 phase reversals with 30 s between blocks and 500 ms 
between phase reversals followed by 5 days of grey screen stimulus. The total amount of time 
elapsed during visual stimulation was the same in all groups.  
For NR2B conditional knockout experiments, mice were presented with 300 s of grey screen 
before a 2 Hz, 0.05 cycles/degree, 100% contrast, 45˚ sinusoidal grating visual stimulus over 5 
blocks of 100 phase reversals with 30 s between blocks and 500 ms between phase reversals for 6 
consecutive days. On day 7, mice were presented with 300 s of grey screen before pseudorandomly 
viewing interweaved blocks of 45˚ and 135˚ sinusoidal grating visual stimulus at 2 Hz, 0.05 
cycles/degree, 100% contrast, and 5 blocks of 100 phase reversals with 30 s between blocks and 
 26 
500 ms between phase reversals. For spatial acuity tests performed as part of the NR2B conditional 
knockout experiment, mice were presented with 300 s of grey screen before a set of 2 Hz, 100% 
contrast, 15˚ sinusoidal grating visual stimuli over 3 blocks of 50 phase reversals with 30 s between 
blocks and 500 ms between phase reversals at different spatial frequencies, presented in 
pseudorandomly interleaved order: 0.05, 0.1, 0.2, 0.4, 0.5, 0.6, and 0.7 cycles/degree. For contrast 
sensitivity tests performed as part of the NR2B conditional knockout experiment, mice were 
presented with 300 s of grey screen before a set of 2 Hz, 0.05 cycles/degrees, 165˚ sinusoidal 
grating visual stimuli over 3 blocks of 50 phase reversals with 30 s between blocks and 500 ms 
between phase reversals at different contrasts presented in pseudorandomly interleaved order: 1, 
2, 6, 12, 25, 50, and 100%.  
For the NR2B pharmacological inhibition experiment, mice were presented with 300 s of grey 
screen before different visual stimulus conditions. On day 1, mice were presented with a 2 Hz, 
0.05 cycles/degree, 100% contrast, 135˚ sinusoidal grating visual stimulus over 5 blocks of 100 
phase reversals with 30s between blocks and 500 ms between phase reversals. Mice were injected 
immediately after this exposure, and 30-60 min later, mice were shown a 2 Hz, 0.05 cycles/degree, 
100% contrast, 45˚ sinusoidal grating visual stimulus over 5 blocks of 100 phase reversals with 
30s between blocks and 500 ms between phase reversals. On day 3, mice were presented with a 
set of 2 Hz, 0.05 cycles/degree, 100% contrast sinusoidal grating visual stimuli over 5 blocks of 
100 phase reversals with 30s between blocks and 500 ms between phase reversals at 45˚, 75˚, and 
135˚. On day 7, mice were presented with a set of 2 Hz, 0.05 cycles/degree, 100% contrast 
sinusoidal grating visual stimulus over 4 blocks of 100 phase reversals with 30s between blocks 
and 500 ms between phase reversals at 45˚, 75˚, 105˚, and 135˚. 
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3.7  Behavioral Data Acquisition and Analysis 
Behavioral vidget responses were measured via piezoelectric sensor placed under the forepaws 
of head-restrained mice presented with visual stimuli. Head-fixed behavior was recorded 
continuously and automatically without experimenters in the same room as the mice. Vidget 
magnitudes were obtained by calculating the root mean square of the voltage signal during each 5 
s interval following the onset of each block of visual stimulation. All vidget magnitudes were 
normalized to the forepaw movements recorded 2 s prior to the delivery of visual stimuli, reported 
in arbitrary units (a.u). Behavioral analysis was conducted with custom MATLAB scripts by an 
experimenter blind to the experimental condition.  
3.8 Electrophysiological Data Acquisition and Analysis 
Electrical activity in V1 elicited by visual stimulus were recorded via implanted extracellular 
local field electrodes connected to the electrophysiology recording system (Recorder-64) (1-kHz 
sampling and a 500-Hz low-pass filter). VEP data were analyzed using custom MATLAB scripts 
by an experimenter blind to the experimental condition. VEP magnitudes were calculated as the 
average peak-trough N1-to-P1 component difference measured during a 300 ms period for each 
distinct stimulus presented on each day. All VEP magnitudes are reported in µV.  
3.9 Visual Cortex Extraction 
For biochemical analysis, mice were deeply anesthetized using 3% isoflurane (chamber). 
Anesthetised animals were decapitated using large scissors, and whole brains were extracted by 
dissecting the fascia and skull. Extracted brains were incubated immediately in chilled, carbogen-
infused artificial cerebrospinal fluid (ACSF, 87 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 
mM NaHCO3, 0.5 mM CaCl2, 7 mM MgCl2, 20 mM D-(+)-glucose, 1.3 mM L-ascorbate, and 75 
mM sucrose) (Sigma-Aldrich) on a petri dish. Brains were cut along the transverse fissure using a 
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scalpel to separate the cerebrum from the cerebellum, pons, medulla, and brain stem. The two 
hemispheres of the brain were then separated by cutting along the central sulcus using a scalpel. 
The brain was then cut posterior to the thalamus to remove the midbrain. The brain was carefully 
dissected to isolate and remove the visual and frontal cortices. Dissected tissues were flash frozen 
with liquid nitrogen and stored at -80˚C for further analysis. 
3.10 Perfusion 
For immunohistochemistry, mice were anesthetized with Fatal-Plus (60 mg/kg pentobarbital) 
via intraperitoneal injection and perfused intracardially with 4% paraformaldehyde in 0.1 M 
phosphate buffered saline. Following perfusion, mice were decapitated using large scissors, and 
skin and fascia were dissected from the skull. The brain was then extracted from the skull and post-
fixed in 4% paraformaldehyde in 0.1 M phosphate buffered saline for 24 hours at 4˚C. 
3.11 Immunohistochemistry 
After fixation in 4% paraformaldehyde in 0.1 M phosphate buffered saline, brains were 
sectioned into 50 µm-thick coronal slices using a vibratome. Slices were treated with blocking 
solution (0.1% Triton-X in phosphate buffered saline) and shaken for 10 min at room temperature. 
Following two phosphate buffered saline washes, slices were treated with Nissl (NeuroTrace 
640/660; Invitrogen; 1:100 dilution) and Hoescht stain (Hoescht 33342; ThermoFisher Scientific; 
1:10,000 dilution) and shaken for 20 min at room temperature. Slices were then washed once with 
blocking solution and three times with phosphate buffered saline. Slices were mounted with 
ProLong Diamond antifade media (ThermoFisher). Images were acquired via confocal 
fluorescence microscopy via 4x and 10x objective lenses (Olympus). The confocal filter sets were 
405 nm (Hoechst), 488 nm (GFP), and 647 (far-red).  
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3.12 Western Blot and Image Analysis  
Western blot was performed in accordance with established laboratory procedures. Thawed 
brain tissues were treated with 100 µL of radioimmunoprecipitation assay (RIPA) buffer prior to 
tissue homogenization. Homogenized tissue was centrifuged for 15 min at 16100 rcf, and the 
supernatant was extracted and diluted 1:20 in RIPA buffer. As protein concentration in each 
extraction can vary with sample handling and size, a bicinchoninic acid (BCA) protein assay was 
performed. 150 mg of protein in RIPA buffer were then treated with 5% v/v b-mercaptoethanol 
(bME) in a sodium dodecyl sulfate (SDS) solution. 
10 mg of total protein treated with bME/SDS were resolved on a 7.5% polyacrylamide gel 
(BioRad) in Tris/glycine/SDS buffer (150 V, 3A, and 300 W for 48 min) along with Protein Dual 
Color Standards. Proteins within the gel were transferred to the nitrocellulose membrane via Bio-
Rad Trans-Blot Turbo Transfer System machine in transfer buffer (Trans-Blot Turbo Transfer 
Buffer and 20% ethanol in water). Following confirmation of protein transfer with red Ponceau S 
solution, the nitrocellulose membrane was washed once with water and TBS-T buffer and 
incubated in Odyssey Blocking Buffer. Nitrocellulose membranes were then excised with a scalpel 
and treated with primary antibody solution (0.1% TWEEN-20 and 0.03-0.1% primary antibody in 
blocking buffer) at 4˚C overnight on rotators. Primary antibodies used in this protocol are listed 
here: monoclonal mouse anti-NR2B antibody (MA1-2014, lot# SK260648; Invitrogen; 1 mg/mL), 
monoclonal rabbit anti-NR1 antibody (ab109182, lot# GR3174915-7; Abcam; 0.483 mg/mL), 
monoclonal rabbit anti-NR2A antibody (ab124913, lot# GR25196-12; Abcam; 1.903 mg/mL), and 
monoclonal mouse anti-b-actin antibody (A5441, lot# 026M4780V; Sigma; 2 mg/mL). 
Following three washes with TBS-T buffer, the nitrocellulose membrane was treated with 
secondary antibody solution (0.1% TWEEN-20, 0.02% IRDye 800CW donkey anti-rabbit 
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antibody (LI-COR), and 0.01% IRDye 680RD donkey anti-mouse antibody (LI-COR) in blocking 
buffer) and shaken for 60 min. After three washes with TBS-T and then with TBS to remove 
unbound or weakly bound antibodies, the membrane was imaged on the ChemiDoc MP Imaging 
System with 800CW (green) and 680RD (red) channels. 
Bands corresponding to NR2A/NR2B/NR1 and b-actin were detected based on molecular 
weight in the gel (165 kDa, 166 kDa, 105 kDa, and 13.5 kDa, respectively). The intensity of each 
band was estimated using ChemiDoc MP software tools and automatically adjusted to account for 
background fluorescence. Band volumes corresponding to NR2A, NR2B, and NR1 were first 
normalized to the band volumes of b-actin from each sample. b-actin-normalized band volumes 
corresponding to NR2A and NR2B were then normalized to b-actin-normalized band volumes 
corresponding to NR1 from each sample. The ratio of NR2A to NR2B band volumes, each 
normalized to b-actin and NR1, were calculated to determine the relative subunit enrichment from 
each sample. Data analysis for relative protein concentration and NR2A/NR2B were performed 
on MATLAB. 
3.13 Statistical Analysis 
 Data collected are presented graphically with individual data points/bars representing 
group means with error bars represent standard error of the mean (SEM). Statistical analysis was 
primarily performed on GraphPad PRISM from data generated in MATLAB. For the NMDA 
receptor subunit composition protein quantification, one-way repeated-measures analysis of 
variance (ANOVA) were performed, with samples matched by western blot membrane. For all 
other experiments, including genetic and pharmacological inhibition of NR2B, two-way repeated 
measures ANOVA were conducted with the test day or visual stimulus as the within-subjects 
factor, and treatment condition as a between groups factor. To further explore differences between 
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groups or stimuli analyzed via two-way repeated-measures ANOVA, Sidak’s multiple comparison 
test was also used post-hoc. A 0.05 alpha value was used as the threshold for significance, and we 
reported the exact p values obtained from our statistical analysis except when p < 0.0001. Adjusted 
p values obtained from Sidak’s correction for multiple comparisons for individual comparisons 
were also reported. Although it is statistically inappropriate to compare groups with small sample 
sizes (n = 2-5), as we are not properly able to conduct tests for normality and homogeneity of 




4  Results 
In order to better understand the biochemistry underlying NMDA receptor function in visual 
memory, we sought to describe NMDA receptor subunit exchange during familiarization with 
visual stimuli and elucidate the function of subunit NR2B in SRP and OSH, manifestations of 
visual memory. To achieve our first aim, we exposed mice to different sets of visual stimulation 
protocols for six days, isolated mouse V1 tissue, and measured NR2A and NR2B proteins levels 
via Western blot. With regards to our second goal, we approached the investigation of NR2B in 
three ways: 1) we generated NR2B loss-of-function animals by genetically ablating NR2B in 
binocular V1 specifically using Cre recombinase, 2) we inhibited NR2B systemically via 
intraperitoneal injection of selective NR2B antagonist CP-101,606, and 3) we inhibited NR2B 
systemically via intraperitoneal injection of a second selective NR2B antagonist, Ro 25-6981. All 
NR2B loss-of-function animals and matched control animals were then subjected to visual 
stimulation protocols for seven days, and SRP and OSH were measured in all animals via 
bilaterally implanted electrodes in binocular V1 and piezoelectric forepaw sensors, respectively. 
Here, we report the key findings from our experiments. 
4.1 NR2B to NR2A subunit exchange during the acquisition of SRP 
In order to track changes in NMDA receptor subunit composition during the acquisition of 
visual memory, we subjected male and female wild-type (p27-29) C57BL/6N mice to 1 of 4 six-
day visual stimulation protocols and subsequently measured NMDA subunit protein expression in 
V1 via Western blot. Visual stimulus protocols included a) daily exposures to a static grey screen 
stimulus, which was intended to serve as a true negative control, b) daily exposure to a full-field 
oriented grating stimulus phase-reversing at 2 Hz (100 phase reversals), that was  previously shown 
to induce and fully saturate SRP (Cooke et al., 2015) and two additional conditions, in which mice 
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were exposed to the phase-reversing grating stimulus only on c) day 6 or d) day 1 of training (Fig. 
8A). The latter conditions were intended to dissociate the effects of stimulus repetition and time 
since training, as biochemical changes might occur gradually after experience. NR2A and NR2B 
quantities were determined from Western blot analysis and normalized against NR1 and b-actin 
levels. In V1, we observed no statistical difference in the NR2A/NR2B ratio among the different 
groups (n = 5) (one-way repeated-measures ANOVA, F2,8 = 1.205, p = 0.3488) (Fig. 8B), 
suggesting that NMDA receptor composition may not change significantly during the short time 
course of our experimental design (six days). Cortical tissue from the frontal cortex was also 
subjected to Western blot analysis in order to serve as a control for non-specific changes in NMDA 
receptor composition (Fig. 8C). Generally, the frontal cortex is less responsive to simple visual 
cues than is V1, so NMDA receptor composition should not change significantly across visual 
stimulus conditions (one-way repeated-measures ANOVA, F2,8 = 0.4338, p = 0.6624). However, 
we observed considerable variability in frontal cortical NMDA receptor composition, likely 
reflecting the small sample size (Fig. 8C). Interestingly, while there were no statistically 
significant differences in the NR2A/NR2B ratio between mice treated with the SRP protocol and 
mice treated with the three control conditions in both regions of the cortex, there is a general trend 
toward increased NR2A and NR2B expression in both V1 and the frontal cortex of mice treated 
with the SRP protocol (Fig. S1; Fig. S2), though these differences are admittedly not statistically 
significant. Taken together, our preliminary findings suggest that the subunit composition of 
NMDA receptors in V1 of C57BL/6N mice does not change significantly during the acquisition 
of SRP over six days beginning on p27-29. 
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Figure 8: NR2A/NR2B ratios in the visual and frontal cortices do not change significantly 
following the acquisition of SRP. (A) Mice were surgically affixed with a headpost for head 
stabilization. Following recovery, mice were presented with a grey screen over 2 days to 
acclimatize mice to the recording rig before exposure to one of four experimental conditions: a) 
static grey screen stimulus daily for 6 days (n = 5); b) 100 phase reversals of a full-field, 45° grating 
stimulus distributed into 5 blocks daily for 6 days (SRP; n = 5); c) static grey stimulus daily for 5 
days followed by 5 blocks of 45° grating stimulus on day 6 (n = 5); d) 45° grating stimulus (five 
blocks) on day 1 followed by a static grey stimulus daily for the remaining 5 days (n = 5). (B) The 
NR2A/NR2B ratio determined via Western blot of visual cortical tissue does not differ 
significantly among the four experimental groups (n = 5). Plotted data has been normalized to the 
NR2A/NR2B ratio of the grey screen negative control group for each Western blot membrane (for 
each brain region, tissue from an equal number of animals from each group were loaded into every 
gel). (C) The NR2A/NR2B ratio in frontal cortical tissue does not differ significantly among the 
four groups of mice included in the experiment (n = 5). All statistical analysis was performed via 







4.2 Effect of NR2B knockout on the acquisition of SRP and OSH 
 
Figure 9: Virally induced GFP expression in CaMKII-expressing cells was diffuse in the 
visual cortex of control mice. (A) GFP expression (green) in mice injected with AAV8-CaMKII-
GFP in the binocular region of V1 was robust and detectable in multiple regions of the cortex, 
including V1, by confocal microscopy. (B) Re-imaged region of interest from panel A with higher 
sensor sensitivity to detect weaker GFP signals throughout cortex. (C) Overlay of panel A with 
GFP, Hoechst (blue, DNA, 1:10,000 dilution), and Nissl (red, neuronal cell bodies, 1:100 dilution). 
 
 Our overarching hypothesis is that the NR2A/NR2B ratio regulates the ability of the 
NMDA receptor to initiate cortical synaptic plasticity in response to experience. Thus, we 
predicted that the NR2A/NR2B ratio would modulate the acquisition of SRP and, therefore, the 
formation of visual memory. To test whether NR2B-containing NMDA receptors are necessary 
for SRP and OSH, we sought to determine the effects of a genetic loss of NR2B subunits. To do 
so, C57BL/6 mice modified to contain LoxP sites flanking the endogenous NR2B gene (Grin2b) 
were locally injected with a virus (AAV8-CaMKII-Cre-GFP) at multiple depths within V1, to 
express Cre recombinase in excitatory cells within all six cortical layers. The expression of Cre 
recombinase in CaMKII+ cells causes the Grin2b gene to be excised, thereby effectively knocking 
out Grin2b in adult tissues. In order test the specificity of this approach qualitatively, we also 
injected the binocular region of V1 in LoxP-Grin2b-LoxP littermates with a control AAV8 
expressing GFP under the control of a CaMKII promoter. Following experimentation, we 
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visualized brain tissue via confocal microscopy. Robust GFP expression was observed in the 
injection site, including V1, and extending to surrounding tissues, including V2, which lies 
adjacent to the binocular region in lateral V1 (Fig. 9). Within V1, strong GFP expression was 
observed in cells in cortical layers 2/3 and 5, but this was much more restricted in layers 4 and 6 
(Fig. 9). Images captured at higher sensitivity demonstrated that the expression of GFP is widely 
observed in the cortex (Fig. 9B), potentially raising the concern that mice injected with an AAV8 
expressing Cre recombinase will lose NR2B expression in tissues other than V1, reducing the 
selectivity of our manipulation. 
 
Figure 10: Virally induced Cre-GFP expression in CaMKII-expressing cells was sparse and 
restricted to the primary visual cortex of injected mice. (A) GFP expression (green) in mice 
injected with AAV8-CaMKII-Cre-GFP in V1 was low and detectable in multiple cortical layers 
of V1 (L2/3 and L5) by confocal microscopy. The surrounding cerebral tissue also appears green 
likely due to the confocal microscope’s high sensor sensitivity and low signal-to-noise. (B) 
Overlay of Fig. 10A with GFP, Hoechst (blue, DNA, 1:10,000 dilution), and Nissl (red, neuronal 
cell bodies, 1:100 dilution). 
 
To qualitatively determine the efficacy of Cre-mediated recombination in V1, we injected 
AAV8 expressing Cre recombinase and GFP under the control of the CaMKII promoter in V1 of 
LoxP-Grin2b-LoxP mice and visualized brain tissue via confocal microscopy. We observed 
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overall weaker GFP expression in cells of layers 2/3 and 5 of V1 and within some of the 
surrounding tissues (Fig. 10). We noted that surrounding neural tissue also had high background 
autofluorescence, as we compensated for weak GFP expression by overexposing the image. 
Visually, the level of fluorescence observed was less than that observed in Fig. 9, suggesting that 
either the efficiency of the AAV8 injected into our experimental group was poor or the Cre-
mediated recombination triggered a loss of infected cells. As Cre-mediated recombination is highly 
efficient, V1 neurons that did express GFP, and therefore, Cre, were assumed to have also 
undergone Cre-mediated recombination. 
 
Figure 11: Spatial acuity and contrast sensitivity are mostly preserved in NR2B KO mice 
relative to control animals. Control mice injected with AAV8-CaMKII-GFP (n = 2) and NR2B 
KO mice injected with AAV8-CaMKII-Cre-GFP (n = 3) were implanted with electrodes bilaterally 
in layer 4 of binocular V1 to record electrical activity and a headpost for head stabilization. 
Following recovery, mice were presented with a grey screen for 2 days to acclimatize mice to the 
recording rig. (A) Head-fixed control (n = 2) and NR2B KO mice (n = 3) were exposed to a 2 Hz 
phase-reversing, full-field, 100% contrast, 15˚ sinusoidal grating stimulus presented across a range 
of spatial frequencies (0.05, 0.1, 0.2, 0.4, 0.5, 0.6, 0.7 cycle/degree) (50 phase reversals over 3 
blocks). Control and NR2B KO mice are able to distinguish between visual stimuli at different 
frequencies, and as frequency increases, VEP magnitude decreases (two-way repeated-measures 
ANOVA, F1.218,3.653 = 8.233, p = 0.0488 for spatial frequency effects). (B) Head-fixed control (n = 
2) and NR2B KO mice (n = 3) were exposed to a 2 Hz phase-reversing, full-field, 0.05 
cycle/degree, 165˚ sinusoidal grating stimulus presented across a range of contrasts (1, 3, 6, 12, 
25, 50, 100%) (50 phase reversals over three blocks). Control and NR2B mice are able to 
distinguish between visual stimuli at different contrasts, and as contrast increases, VEP magnitude 
increases (two-way repeated-measures ANOVA, F1.165,3.496 = 10.12, p = 0.0392 for contrast 




As manipulations of V1 can cause neurological damage that may affect physiological function, 
we assessed visual acuity and contrast sensitivity in N2RB KO (n = 3) and control mice (n = 2) by 
measuring VEP magnitudes elicited in layer 4 of binocular V1 during exposure to a 2 Hz phase-
reversing, full-field, 100% contrast, sinusoidal grating stimulus across a range of spatial 
frequencies (0.05-0.7 cycle/degree) and contrasts (1-100%) (50 phase reversals over three blocks). 
Overall, VEP magnitudes in both NR2B KO and control mice decreased with increasing spatial 
frequency (Fig. 11A; two-way repeated-measures ANOVA, F1.218,3.653 = 8.233, p = 0.0488 for the 
main effect of spatial frequency), suggesting that the animals were less able to resolve finer details. 
It is worth mentioning, however, that individual differences in VEP among different frequencies 
were not statistically significant when analyzed via Sidak’s multiple comparison test post-hoc, 
likely a result of the small sample size and Sidak’s correction for multiple comparisons. There 
were no statistically significant differences in VEP magnitudes measured in NR2B KO and control 
mice (two-way repeated-measures ANOVA, F1,3 = 6.369, p = 0.0859 for the main effect of 
genotype; two-way repeated-measures ANOVA, F6,18 = 1.724, p = 0.1726 for the interaction of 
genotype ´ spatial frequency). Similarly, VEP magnitudes in both NR2B KO and control mice 
increased with increasing stimulation contrast (Fig. 11B; two-way repeated-measures ANOVA, 
F1.165,3.496 = 10.12, p = 0.0392 for main effect of contrast), indicating that both groups of mice were 
able to distinguish between different contrasts, although it may be statistically inappropriate to 
compare groups with such small sample sizes. Again, it is important to note that individual 
differences in VEP among different contrasts were not statistically significant when analyzed via 
Sidak’s multiple comparison test post-hoc. There were no statistically significant differences in 
VEP magnitudes measured in NR2B KO and control mice (two-way repeated-measures ANOVA, 
F1,3 = 2.638, p = 0.2028 for the main effect of genotype; two-way repeated-measures ANOVA, 
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F6,18 = 1.422, p = 0.2605 for the interaction of genotype ´ contrast). Taken together, our data 
demonstrates that NR2B KO mice exhibit sensitivity to spatial acuity and contrast, but a trend 
towards overall smaller VEP magnitudes. As a result, we cannot definitively rule out abnormal 
vision and visual processing in V1. 
In order to determine the role of NR2B in SRP and OSH, after injection with either AAV8-
CaMKII-Cre-GFP (n = 3) or control AAV8-CaMKII-GFP (n = 2) into binocular V1, we subjected 
Grin2bfl/fl mice to a visual stimulation protocol known to elicit SRP and OSH. SRP and OSH were 
measured via electrodes bilaterally implanted in layer 4 of binocular V1 and piezoelectric sensors 
placed under the forepaws, respectively (Fig. 12A). Although it is statistically inappropriate to 
compare groups with such small sample sizes, as we cannot properly conduct tests for normality 
and homogeneity of variance, we nevertheless performed two-way repeated-measures ANOVA to 
compare the effects of genotype and time. In control animals, VEP magnitudes appeared to 
increase briefly from day 1-3 with further exposure to a 2 Hz phase-reversing, full-field, 0.05 
cycle/degree, 100% contrast, 45˚ sinusoidal grating stimulus (100 phase reversals) before 
plateauing and decreasing from day 4-6, though differences in VEP magnitudes measured daily 
are not statistically significant (Fig. 12B) (two-way repeated-measures ANOVA, F1.533,4.600 = 
2.609, p = 0.1751 for the main effect of treatment day; two-way repeated-measures ANOVA, F5,15 
= 1.239, p = 0.3397 for the interaction of genotype ´ treatment day), likely reflecting the small 
sample size. Similarly, VEP magnitudes measured in NR2B KO animals remained relatively 
constant from day 1-6 (Fig. 12B). Although the measured differences were not statistically 
significant, we noted a visible difference in overall VEP magnitude between control and NR2B 
KO mice, with the former exhibiting larger VEP magnitudes than the latter (two-way repeated-
measures ANOVA, F1,3 = 8.212, p = 0.0643 for the main effect of genotype). Furthermore, we did 
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not observe any statistically significant changes in VEP magnitudes when control and NR2B KO 
mice were exposed to novel stimuli on day 7 (Fig. 12C) (two-way repeated-measures ANOVA, 
F1,3 = 3.380, p = 0.1633 for the main effect of genotype; F1,3 = 4.043, p = 0.1379 for the main effect 
of stimulus). Taken together, these preliminary data cannot definitively characterize the role of 
NR2B in the acquisition of SRP in p56-66 C57BL/6 mice, since our observations may be 
confounded by high variance stemming from small sample sizes and methodological challenges. 
In addition to SRP, in NR2B KO (n = 3) and control (n = 2) mice we also examined OSH—a 
reduction in a reflexive behavior—that co-occurs with SRP and relies on NMDA receptor activity 
in V1 (Cooke et al., 2015). Using the same six-day visual stimulation protocol (Fig. 12A), we 
measured vidget magnitudes to the onset of each block of stimuli each day, in both NR2B KO 
mice and control mice, via a piezoelectric sensor placed under the forepaws. Vidget magnitudes 
were normalized to baseline forepaw movements recorded during the 2 s prior to exposure to visual 
stimuli. In both NR2B KO and control mice, we did not observe statistically significant changes 
to vidget magnitude from day 1-6, and vidget magnitude remained relatively constant (Fig. 12D) 
(two-way repeated-measures ANOVA, F1,3 = 0.01, p = 0.9059 for the main effect of genotype; 
F2.353,7.059 = 0.6676 , p = 0.5653 for the main effect of treatment day). Moreover, we did not observe 
any statistically significant changes in vidget magnitudes when control and NR2B KO mice were 
exposed to a novel stimulus on day 7 (Fig. 12E) (two-way repeated-measures ANOVA, F1,3 = 0.89, 
p = 0.4149 for the main effect of genotype; F1,3 = 0.16, p = 0.7158 for the main effect of treatment 
day). From our prior experience, vidget magnitudes decrease with increasing familiarity to visual 




Figure 12: Loss of NR2B may reduce baseline VEP magnitude. (A) Control mice injected with 
AAV8-CaMKII-GFP (n = 2) and NR2B KO mice injected with AAV8-CaMKII-Cre-GFP (n = 3) 
were implanted with electrodes and headpost and acclimatized as described previously. 
Piezoelectric sensors were also placed under the forepaws to measure movement. For the next six 
days, a 45˚ sinusoidal grating stimulus was presented on the monitor. On day 7, both the familiar 
45˚ stimulus and a novel 135˚ stimulus were presented in interleaved order to assess SRP and OSH. 
(B) VEP magnitudes remained relatively constant for control (n = 2) and NR2B KO (n = 3) 
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exposed to six days of a 45˚ sinusoidal grating stimulus, VEP magnitudes do not differ 
significantly between the two groups. Average VEP waveforms are displayed above the graph. 
Vertical scale bar represents 50 µV; horizontal scale bar represents 0.1 s. (C) VEP magnitudes do 
not differ significantly when control (n = 2) or NR2B KO mice (n = 3) are shown familiar and 
novel stimuli on day 7. Average VEP waveforms are also provided above the graph. Vertical scale 
bar represents 50 µV; horizontal scale bar represents 0.1 s. (D) Vidget magnitudes remained 
relative constant in control mice (n = 2) and NR2B KO mice (n = 3) exposed to six days of a 45˚ 
sinusoidal grating stimulus and did not differ significantly between the two groups. (E) Vidget 
magnitudes do not differ significantly when control (n = 2) or NR2B KO mice (n = 3) are shown 
familiar and novel stimuli on day 7. Average vidget waveforms are also provided above the graph. 
Vertical scale bar represents 1 a.u.; horizontal scale bar represents 2 s. Average vidget magnitudes 
were normalized to baseline forepaw movements obtained during the 2 s prior to visual stimuli 
(dotted line). All full-field phase-reversing stimuli were presented at 2 Hz, 0.05 cycle/degree, 
100% contrast, and 100 phase reversals over 5 blocks. Statistical analysis was performed via two-
way repeated-measures ANOVA. Error bars in all graphs represent SEM. 
 
4.3 Effect of NR2B pharmacological inhibition on the acquisition of SRP and OSH 
4.4.1 Effect of NR2B inhibition via CP-101,606 on SRP and OSH 
 
Since we encountered several challenges with the viral injection approach to knockout NR2B, 
including low expression of AAV8 in layer 4 of binocular V1 (Fig. 10) and apparently poor VEP 
potentiation in control animals (Fig. 12B and 12C), we switched to a pharmacological approach 
to inhibit NR2B in order to delineate the role of NR2B in SRP and OSH (Fig. 13A). Wild-type 
mice were initially presented with a 2 Hz, 0.05 cycle/degree, 100% contrast, 135˚ sinusoidal 
grating stimulus (100 phase reversals over five blocks) before being subjected to intraperitoneal 
injections of either 75% v/v DMSO (vehicle control) (n = 5) or 10 mg/kg CP-101,606 (n = 4). One 
hour following injection, mice were presented with a 45˚ sinusoidal grating stimulus (five blocks). 
On day 3, mice in both treatment groups were presented with five blocks of 135˚ (“pre-drug 
familiar”), 45˚ (“post-drug familiar”), and 75˚ (“post-drug novel”) sinusoidal grating stimuli. On 
day 7, all mice were presented with four blocks of the pre-drug familiar 135˚, post-drug familiar 
45˚, post-drug familiar 75˚, and novel 105˚ sinusoidal grating stimuli. VEP and vidget magnitudes 
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were measured via bilaterally implanted electrodes in layer 4 of binocular V1 and piezoelectric 
sensors placed underneath the forepaws, respectively. 
In vehicle-treated mice, VEP magnitudes elicited by the pre-drug familiar 135˚ stimulus was 
lower than the VEP magnitude elicited by the post-drug familiar 45˚ stimulus, indicating that 
DMSO may have a baseline effect on normal physiology (Fig. 13B). VEP magnitudes elicited by 
the pre-drug familiar 135˚ stimulus appeared to increase from day 1-3 and levelled off between 
day 3-7 (Fig. 13B). The initial increase in VEP magnitude, though not statistically significant, 
appears to reflect SRP and suggests successful acquisition and consolidation of cortical plasticity. 
Interestingly, in the same group of mice, VEP magnitudes elicited by the post-drug familiar 45˚ 
stimulus appeared to remain constant between day 1-3 and seemed to only increase from day 3-7 
(Fig. 13B). The constancy of VEP magnitudes during this initial three-day period suggests that 
potentiation may not have occurred, as a result of DMSO. Following washout of DMSO, SRP 
could apparently be induced for this previously unpotentiated response by day 3, as revealed by 
the increase in VEP magnitudes to the post-drug 45˚ stimulus on day 7. VEP magnitudes 
corresponding to the post-drug familiar 75˚ stimulus also increased from day 3-7, suggesting 
normal potentiation and SRP acquisition. Taken together, these data suggest that DMSO alone 
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Figure 13: High concentration DMSO vehicle, not CP-101,606, likely occludes the 
acquisition, but not consolidation, of visual memory. (A) Mice were implanted with electrodes 
and headpost and acclimatized mice as described previously. Mice were then presented with a 135˚ 
sinusoidal grating stimulus (5 blocks) on day 1. On the same day, mice were injected 
intraperitoneally with either vehicle (75% v/v DMSO) (n = 5) or CP-101,606 (10 mg/kg) (n = 4) 
and exposed to a second 45˚ sinusoidal grating stimulus (5 blocks) one hour after injection. On 
day 3, all mice were presented with the pre-drug familiar 135˚ stimulus, post-drug familiar 45˚ 
stimulus, and a novel 75˚ stimulus (5 blocks per stimulus) to assess SRP and OSH. On day 7, all 
mice were presented with the pre-drug familiar 135˚ stimulus, post-drug familiar 45˚ stimulus, the 
previously novel 75˚ stimulus, and a true novel 105˚ stimulus (4 blocks per stimulus) to reassess 
SRP retention and acquisition. VEP magnitudes were measured on day 1, 3, and 7. (B) and (C) 
VEP magnitudes elicited by different orientations pre- and post-drug injection on day 1, 3, and 7 
suggest DMSO inhibits acquisition, but not consolidation, of visual memory in vehicle-treated 
mice (n = 5) and CP-101,606-treated mice (n = 4), respectively. (D) Day 3 VEP magnitudes were 
normalized to day 1 VEP magnitudes (% of Day 1) in vehicle (n = 5) and CP-101,606-treated 
animals (n = 4). There is greater evidence of VEP potentiation elicited by the pre-drug familiar 
135˚ stimulus than the post-drug familiar 45˚ stimulus across both groups (two-way repeated-
measures ANOVA: F1,7 = 26.2, p = 0.0014 for stimulus effects). (E) Day 7 VEP magnitudes were 
normalized to day 3 VEP magnitudes (% of Day 3) in vehicle (n = 5) and CP-101,606-treated 
animals (n = 4). Across both groups, the increase in VEP magnitudes elicited by the pre-drug 
familiar 135˚ stimulus was less than those elicited by both the post-drug familiar 45˚ stimulus and 
the post-drug familiar 75˚ stimulus (two-way repeated-measures ANOVA, F2,14 = 11.26, p = 
0.0012 for stimulus effects). (F) There were no statistically significant differences between 
recorded vidget magnitudes on day 3 in all stimulus conditions and treatment groups. Dotted line 
indicates mean baseline forepaw movement recorded during the 2 s before visual stimulation. All 
full-field phase-reversing stimuli were presented at 2 Hz, 0.05 cycle/degree, 100 phase reversals 
per block, and 100% contrast. Error bars in all graphs represent SEM. ** represents a statistically 
significant comparison with p ≤ 0.01. 
 
Interestingly, the same patterns of potentiation were observed in all stimulation conditions in 
mice treated with 10 mg/kg of known selective NR2B antagonist CP-101,606 (Fig. 13C). Given 
the baseline effects of the DMSO vehicle on VEP magnitudes observed in vehicle control animals, 
the effects of CP-101,606 were not immediately clear. Irrespective of treatment group, VEP 
magnitudes elicited by the post-drug 45˚ visual stimulus were greater than the VEP magnitude 
elicited by the pre-drug 135˚ visual stimulus (two-way repeated-measures ANOVA, F1,7 = 6.430, 
p = 0.0389 for stimulus effects) on day 1. On day 3, the VEP magnitudes elicited by the pre-drug 
familiar 135˚, post-drug familiar 45˚, and post-drug novel 75˚ visual stimuli differed significantly 
(two-way repeated-measures ANOVA, F2,14 = 12.62, p = 0.0007 for stimulus effects). A closer 
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statistical examination via Sidak’s multiple comparison test post-hoc revealed that the pre-drug 
familiar 135˚stimulus potentiated VEPs to a greater extent than the post-drug familiar 45˚ stimulus 
by day 3 (adj. p = 0.0299); the pre-drug familiar 135˚ stimulus also elicited larger VEPs than the 
post-drug familiar 75˚ stimuli (adj. p = 0.0006) on day 3. On day 7, the VEP magnitudes elicited 
by the pre-drug familiar 135˚, post-drug familiar 45˚, and post-drug familiar 75˚ visual stimuli 
differed significantly (two-way repeated-measures ANOVA, F3,21 = 24.24, p < 0.0001 for stimulus 
effects). Again, Sidak’s multiple comparison test revealed that the pre-drug familiar 135˚ stimulus 
potentiated VEPs to a greater extent than the post-drug familiar 75˚ stimulus (adj. p = 0.0006) and 
elicited larger VEPs than the post-drug novel 105˚ stimulus (adj. p < 0.0001). The post-drug 
familiar 45˚ stimulus also potentiated VEPs to a greater extent than the post-drug familiar 75˚ 
stimulus (adj. p = 0.0083) and elicited larger VEPs than the post-drug post-drug familiar 105˚ 
stimulus (adj. p < 0.0001) on day 7.  
In order to closer examine the effect of pharmacological treatment on potentiation, we 
normalized day 3 VEP magnitudes to day 1 VEP magnitudes to determine the change in VEP 
magnitude in vehicle-treated and CP-101,606-treated mice exposed to the pre-drug familiar 135˚ 
and post-drug familiar 45˚ stimuli (Fig. 13D). While no statistically significant differences were 
observed between vehicle-treated mice and CP-101,606-treated mice, suggesting that CP-101,606 
has no observable effect on SRP (two-way repeated-measures ANOVA, F1,7 = 0.39, p = 0.5476 for 
drug effects), we did observe significant differences in VEP magnitudes between mice exposed to 
the pre-drug familiar 135˚ and post-drug familiar 45˚ stimuli (two-way repeated-measures 
ANOVA: F1,7 = 26.2, p = 0.0014 for stimulus effects). Similarly, we normalized day 7 VEP 
magnitudes to day 3 VEP magnitudes in vehicle-treated and CP-101,606-treated mice exposed to 
the pre-drug familiar 135˚, post-drug familiar 45˚, and post-drug novel 75˚ stimuli (Fig. 13E). 
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Again, while no statistically significant differences were observed between vehicle-treated and 
CP-101,606-treated mice (two-way repeated-measures ANOVA, F1,7 = 0.1792, p = 0.6848 for drug 
effects), suggesting that CP-101,606 has no observable effect on SRP, we did observe significant 
differences in VEP potentiation between mice exposed to the pre-drug familiar 135˚, post-drug 
familiar 45˚, and post-drug novel 75˚ stimuli (two-way repeated-measures ANOVA, F2,14 = 11.26, 
p = 0.0012 for stimulus effects). Sidak’s multiple comparison test revealed that the pre-drug 
familiar 135˚ stimulus potentiated VEPs to a greater extent than the post-drug familiar 45˚ stimulus 
(adj. p = 0.0029) and the post-drug novel 75˚ stimulus (adj. 0.0035). Taken together, these data 
support our conclusion that DMSO occludes the acquisition of SRP as visual stimuli presented 
before DMSO-treatment are able to potentiate VEPs, in contrast to stimuli presented immediately 
after DMSO-treatment. 
Given that OSH and SRP emerge in parallel, we also measured vidget magnitudes in all mice 
on day 3. After normalizing day 3 vidget magnitudes to baseline forepaw movements recorded 2 
s prior to visual stimulation, we did not observe any statistically significant differences between 
vehicle-treated and CP-101,606-treated mice and between mice presented with pre-drug familiar 
135˚, post-drug familiar 45˚, and post-drug novel 75˚ stimuli (two-way repeated-measures 
ANOVA, F1,7 = 0.06685, p = 0.8034 for drug effects; F1.778,12.45 = 0.1519, p = 0.8374 for stimulus 
effects).  
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4.4.2 Effect of NR2B inhibition via Ro 25-6981 on SRP and OSH  
  











Figure 14: Selective NR2B antagonist Ro 25-6981 does not appear to attenuate SRP or OSH. 
(A) Mice were implanted with electrodes and headpost and acclimatized as described previously. 
Mice were then presented with a 135˚ sinusoidal grating stimulus (5 blocks) on day 1. On the same 
day, mice were injected intraperitoneally with either vehicle (saline) (n = 2) or Ro 25-6981 (10 
mg/kg) (n = 4) and exposed to a second 45˚ sinusoidal grating stimulus (5 blocks) 30 min after 
injection. From day 3 onwards, mice were subjected to the same visual stimulation protocol used 
in the CP-101,606 NR2B inhibition experiment. (B) and (C) VEP magnitudes elicited by familiar 
orientations on day 1, 3, and 7 appeared to increase in vehicle-treated (n = 2) and Ro 25-6981-
treated mice (n = 4). (D) Day 3 VEP magnitudes were normalized to day 1 VEP magnitudes (% of 
Day 1) in vehicle (n = 2) and Ro 25-6981-treated animals (n = 4). No statistically significant 
differences were observed between pre-drug familiar 135˚ stimulus and post-drug familiar 45˚ 
stimulus or between vehicle and Ro 25-6981-treated animals. (E) Day 7 VEP magnitudes were 
normalized to day 3 VEP magnitudes (% of Day 3) in vehicle and Ro 25-6981-treated animals. 
The increase in VEP magnitudes elicited by the pre-drug familiar 135˚ stimulus or the post-drug 
familiar 45˚ stimulus were smaller than those elicited by the post-drug familiar 75˚ stimulus across 
both groups (two-way ANOVA: F2,8 = 20.0, p = 0.0008 for stimulus effects). (F) There were no 
statistically significant differences between recorded vidget magnitudes on day 3 in all stimulus 
conditions and treatment groups. Dotted line indicates mean baseline forepaw movement recorded 
during the 2 s before visual stimulation. All full-field phase-reversing stimuli were presented at 2 
Hz, 0.05 cycle/degree, 100 phase reversals per block, and 100% contrast. Error bars in all graphs 
represent SEM. ** represents a statistically significant comparison with p ≤ 0.01. 
 
Given a potential baseline effect of DMSO-containing vehicle on SRP, which confounded our 
observations of the effect of CP-101,606 on SRP and OSH, we investigated replacing CP-101,606 
with a second selective NR2B antagonist Ro 25-6981 that is dissolvable in saline (Fig. 14A), 
thereby obviating the use of DMSO. Wild-type mice were initially presented with a 2 Hz, 0.05 
cycle/degree, 100% contrast, 135˚ sinusoidal grating stimulus (100 phase reversals over five 
blocks) before being subjected to intraperitoneal injections of either saline (vehicle control) (n = 
2) or 10 mg/kg Ro 25-6981 (n = 4). Thirty minutes following injection, mice were presented with 
a 45˚ sinusoidal grating stimulus (five blocks). From day 3 onward, mice were subjected to the 
same visual stimulation protocol used in the CP-101,606 NR2B inhibition experiment. 
In vehicle-treated mice (Fig. 14B), the pre-drug familiar 135˚ stimulus appeared to increase 
from day 1-7, suggesting the occurrence of SRP and the acquisition and consolidation of visual 
memory. VEP magnitudes elicited by the post-drug familiar 45˚ stimulus also appeared to increase 
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from day 1-3 and day 3-7, again indicating the occurrence of SRP. There were no statistically 
significant differences between VEP magnitudes measured in either stimulation condition. Stated 
otherwise, the occlusion of visual memory acquisition likely observed following DMSO treatment 
was not seen here. VEP magnitudes elicited by the post-drug familiar 75˚ stimulus also appeared 
to increase from day 3-7 (Fig. 14B).  
In Ro 25-6981-treated mice (Fig. 14C), VEP magnitudes elicited by the pre-drug familiar 135˚ 
stimulus appeared to increase from day 1-3 and then plateaued from day 3-7. This initial increase 
suggests the likely acquisition and consolidation of SRP, as seen in the vehicle-control mice, 
despite treatment with a selective NR2B antagonist. Similarly, VEP magnitudes elicited by the 
post-drug familiar 45˚ stimulus appeared to increase gradually from day 1-7, and VEP magnitudes 
elicited by the post-drug familiar 75˚ stimulus appeared to increase from day 3-7 (Fig. 14C). No 
statistically significant differences were observed between vehicle-treated and Ro 25-6981-treated 
animals in any of the visual stimulation conditions on day 1 (two-way repeated-measures ANOVA, 
F1,4 = 1.942, p = 0.2359 for drug effects), day 3 (two-way repeated-measures ANOVA, F1,4 = 
0.7221, p = 0.4433 for drug effects), or day 7 (two-way repeated-measures ANOVA, F1,4 = 3.962, 
p = 0.1174 for drug effects). Irrespective of treatment group, VEP magnitudes elicited by the pre-
drug familiar 135˚, post-drug familiar 45˚, and post-drug novel 75˚ visual stimuli differed 
significantly on day 3 (two-way ANOVA: F2,8 = 10.82, P = 0.0053 for stimulus effects), though 
VEP magnitudes elicited by the pre-drug familiar 135˚ and post-drug familiar 45˚ stimuli did not 
differ significantly on day 1 (two-way repeated-measures ANOVA, F1,4 = 0.05092 , p = 0.8325 for 
stimulus effects). Sidak’s multiple comparison test revealed that the pre-drug familiar 135˚ 
stimulus elicited larger VEP magnitudes than the post-drug familiar 75˚ stimulus (adj. p = 0.0075) 
and post-drug familiar 45˚ stimulus elicited larger VEP magnitudes post-drug familiar 75˚ stimuli 
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(adj. p = 0.0196) on day 3. Similarly, day 7 VEP magnitudes elicited by the pre-drug familiar 135˚, 
post-drug familiar 45˚, post-drug familiar 75˚, and post-drug novel 105˚ visual stimuli differed 
significantly (two-way ANOVA: F3,12 = 12.97, P = 0.0004). Again, Sidak’s multiple comparison 
test revealed that the pre-drug familiar 135˚ stimulus elicited larger VEP magnitudes than the post-
drug novel 105˚ stimulus (adj. p = 0.0012) and the post-drug familiar 45˚ stimulus elicited larger 
VEP magnitudes than the post-drug novel 105˚ stimulus (adj. p = 0.0011).  
To explore changes in VEP magnitudes between vehicle-treated and Ro 25-6981-treated mice 
exposed to the pre-drug familiar 135˚ and post-drug familiar 45˚ stimuli, we normalized day 3 
VEP magnitudes to day 1 VEP magnitudes (Fig. 14D). No statistically significant differences were 
observed between vehicle-treated mice and Ro 25-6981-treated mice (two-way repeated-measures 
ANOVA, F1,4 = 0.008359 , p = 0.9315 for drug effects), which support our prior observation that 
Ro 25-6981 has no observable effect on SRP, and between mice exposed to the pre-drug familiar 
135˚ and post-drug familiar 45˚ stimuli (two-way repeated-measures ANOVA, F1,4 = 0.005116, p 
= 0.9464 for stimulus effects). We also normalized day 7 VEP magnitudes to day 3 VEP 
magnitudes in vehicle-treated and Ro 25-6981-treated mice exposed to the pre-drug familiar 135˚, 
post-drug familiar 45˚, and post-drug novel 75˚ stimuli (Fig. 14E). Interestingly, while no 
statistically significant differences were observed between vehicle-treated and Ro 25-6981-treated 
mice (two-way repeated-measures ANOVA, F1,4 = 1.41 , p = 0.2998 for drug effects), we saw 
significant differences in VEP magnitudes between mice exposed to the pre-drug familiar 135˚, 
post-drug familiar 45˚, and post-drug novel 75˚ stimuli (two-way ANOVA, F2,8 = 20.0, p = 0.0008 
for stimulus effects; F2,8 = 8.64, p = 0.01 for stimulus ´ drug interaction). It is worth noting, 
however that Sidak’s multiple comparison test failed to identify any statistically significant 
differences in day 7 VEP magnitudes between stimulation conditions, likely due to Sidak’s 
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correction for multiple comparisons and the small control sample size. Taken together, these data 
suggest that despite its role in the selective inhibition of NR2B, Ro 25-6981 likely does not affect 
SRP acquisition or consolidation, although it does appear to influence the potentiation of VEPs to 
novel stimuli presented 48 hours following injection. This could reflect some type of compensatory 
homeostatic shift in NMDA receptor expression or composition. 
As before, we also measured vidget magnitudes in all mice on day 3 to examine the effects of 
Ro 25-6981 on OSH. After normalizing day 3 vidget magnitudes to baseline forepaw movements 
recorded 2 s prior to visual stimulation, we did not observe any statistically significant differences 
between vehicle-treated and Ro 25-6981-treated mice (two-way repeated-measures ANOVA, F1,4 
= 1.41 , p = 0.2998 for drug effects) and between mice presented with pre-drug familiar 135˚, post-
drug familiar 45˚, and post-drug novel 75˚ stimuli (two-way repeated-measures ANOVA, F1,4 = 




5.1 NMDA receptor subunit composition in V1 neurons does not change during SRP 
The goals of this project were two-fold: to describe how the subunit composition of NMDA 
receptors expressed in neurons of V1 change during the acquisition of visual memory, and to 
elucidate the role of NMDA receptor subunit NR2B in correlates of recognition memory, SRP and 
OSH. We were unable to observe any statistically significant changes to the NR2A/NR2B ratio in 
mice that underwent a visual stimulation protocol previously reported to elicit SRP based on 
protein quantification via Western blot, suggesting that at least during the 6-day time course of our 
experiment, NMDA receptor subunit expression does not change at the level of non-fractionated 
homogenates. Rapid NMDA receptor subunit composition changes have previously been reported 
in 1-6-week-old dark-reared rats upon light exposure, suggesting a rapid change in NMDA 
receptor biochemistry with increasing visual experience (Quinlan et al., 1999). It is worth noting 
that in these past reports, animals undergo substantive changes in visual experience, from never 
having been exposed to their visual environments to full stimulation of V1 via new visual inputs, 
perhaps explaining the significant alterations in NMDA receptor composition. In contrast to our 
current work, while mice are able to recognize a sinusoidal grating 45˚ stimulus presented over the 
course of 6 days, the magnitude of the stimulus may not be sufficient to generate detectable 
changes to the NR2A/NR2B ratio.  
Interestingly, despite the absence of significant differences between the different stimulation 
conditions, there appears to be a tendency towards increased NR2B and NR2A expression in all 
mice that were presented with non-grey screen stimuli (sinusoidal grating 45˚ stimulus for a single 
day or 6 days) with no concordant changes in NR1 expression (Fig. S1; Fig. S2). Taken together, 
these trends suggest that while the total number of NMDA receptors do not change based on the 
number of obligatory NR1 subunits, visual experience enhances NR2B and NR2A expression 
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levels. Recognizing that functional NMDA receptors must contain two NR1 subunits and two, 
variable NR2/3 subunits and that the replacement of NR2B by NR2A occurs during the production 
of new NMDA receptors only, we propose several explanations for our observations here. First, it 
is possible that we are unable to appreciate statistically significant changes in NR1 expression 
given its high baseline expression level. Second, though the focus of our experiment was on NR2A 
and NR2B, it is possible that NMDA receptors containing other subunits, including NR2C, NR2D, 
or any of the NR3 subtypes, which play a role in visual memory, may be expressed to replace the 
existing NR2B-containing NMDA receptors. Finally, the increase in NR2A and NR2B expression 
reflect a pool of NMDA receptor subunits that have yet to be assembled to form new NMDA 
receptors or a pool of intact NMDA receptors that have yet to be degraded. This hypothesis 
suggests a possible time-lag between visual memory acquisition and NMDA receptor subunit 
exchange. Further experiments are needed to investigate and distinguish between these hypotheses 
to fully elucidate biochemical changes to NMDA receptors during visual memory acquisition. 
With regards to detection sensitivity, it is also important to recognize limitations in our 
methodology. In addition to a small sample size (n = 5), which may contribute to larger variances 
in the data and obscure potentially significant findings, our experiment was conducted such that 
V1 cortical tissue was dissected and homogenized for protein extraction. Since dissection was 
performed manually, and there are no consistent anatomical markers for boundaries around V1, it 
is possible that cortical regions other than V1 were also isolated along with V1. Since visual 
stimulus-dependent changes likely predominantly affect V1, we would not expect there to be 
changes in NMDA receptor subunit composition outside of V1. As the frontal cortex had been 
used in previous monocular deprivation experiments in the Bear Lab, this guided our choice in 
using frontal cortical tissue as a negative control in our experiment. If there were indeed changes 
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in NMDA receptor composition in V1 during the acquisition of visual memory, the presence of 
proteins from non-V1 cortical regions may have obscured these changes by diluting the magnitude 
of the change. Future experiments may be able to eliminate these potential sources of error by 
increasing sample size to enhance statistical power and by selectively isolating V1 neurons via 
synaptoneurosome fractionation. Given that NMDA receptor subunits are functional on the 
synaptic membrane only, future iterations of our experiments may also opt to use specialized 
techniques, including subcellular fractionation, to isolate plasma membrane proteins for analysis 
in order to increase the signal-to-noise ratio. It is worth mentioning that relative NR2A, NR2B, 
NR1, and b-actin levels were quantified using Western blot and software tools to analyze protein 
immunoblot images. As detection sensitivity is limited by computer algorithms and the resolution 
of the images generated, which may underreport proteins present at higher concentrations, our 
ability to accurately quantify proteins may be called into question. Future iterations of this project 
may seek to use more sophisticated tools to quantify specific proteins, including mass spectrometry 
or enzyme-linked immunosorbent assay. 
5.2 Genetic ablation of NR2B was unable to reveal the role of NR2B in SRP and OSH 
In order to delineate the role of NMDA receptor subunit NR2B in SRP and OSH, we selectively 
deleted Grin2b in Grin2bfl/fl mice via viral infection with AAV8-CaMKII-Cre-GFP and measured 
SRP and OSH during visual stimulation four weeks post-infection. Given that there were no 
statistically significant differences in VEP magnitudes measured within NR2B KO mice and 
control mice (Grin2bfl/fl mice injected with AAV8-CaMKII-GFP) groups or between the two 
groups, we were unable to determine the role of NR2B in SRP and OSH (Fig. 12). A closer 
examination of the data suggests that there may be a statistically insignificant upward trend in VEP 
magnitudes and a downward trend in vidget magnitudes in both groups of mice across the 6 days 
 56 
of visual stimulation, perhaps suggesting the manifestation of SRP and OSH, respectively, and 
implying that NR2B knockout may not affect the acquisition of visual memory (Fig. 12). However, 
no definitive conclusions can be drawn given that SRP and OSH were not observed as expected 
from our prior work (Cooke et al., 2015). Visual function (spatial acuity and contrast sensitivity) 
was preserved in both groups of mice (Fig. 11), and VEP waveforms look consistent with previous 
reports, suggesting no issues with normal electrophysiology in both groups of mice (Fig. 12B and 
12C) (Cooke et al., 2015; Frenkel et al., 2006). Interestingly, though statistically insignificant, 
there appears to be a difference between average VEP magnitudes measured in control mice 
compared to those measured in NR2B KO mice, suggesting that the loss of NR2B decreases 
responsiveness to visual stimuli. Given that prior research on related NMDA receptor subunit 
NR2A has demonstrated that a loss of NR2A function enhances synaptic strengthening while 
diminishing synaptic weakening, leading to increased potentiation in monocular deprivation 
experiments (Cho et al., 2009; Massey et al., 2004; Philpot et al., 2007), the loss of NR2B may 
cause the opposite effect, namely the enhancement of synaptic weakening and the inhibition of 
synaptic strengthening. This theory may potentially be consistent with our findings of reduced 
VEP magnitudes in NR2B KO mice here. Alternatively, the loss of NR2B may result in the 
compensatory overexpression of NMDA receptor subunits NR1 and NR2A, leading to a larger 
number of synaptic NMDA receptors and enhanced potentiation. This hypothesis is supported by 
prior observations, which demonstrated that the genetic ablation of NR1 or inhibition of NMDA 
receptors in general both abolished SRP and reduced baseline VEP magnitudes elicited by a novel 
stimulus. This latter effect mirrors our observations here. We must recognize, however, that there 
is evidence that may refute our hypothesis. Indeed, selective disruption of NR2A does not lead to 
the compensatory overexpression of NR1 and NR2B (Philpot et al., 2007). While this finding does 
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not preclude our hypothesis, future iterations of our experimental approach may opt to examine 
NR1 and NR2A expression levels following selective NR2B deletion. 
There are several potential caveats and alternative explanations for our findings. First, it is 
important to acknowledge the inconsistent infectivity of AAV8 and its imprecise expression in 
binocular V1. In AAV8-CaMKII-GFP-infected mice, confocal fluorescence microscopy indicated 
high levels of infection, as evidenced by the presence of GFP expression in cortical areas outside 
of lateral V1, including V2 (Fig. 9). These control mice also did not exhibit SRP and OSH, which 
may be attributable to the small sample size (n = 2) (Fig. 12) or physiological effects related to 
AAV8 infection. This latter hypothesis is supported by prior work, which has suggested that 
AAV8-induced GFP expression is associated with toxicity in rat hippocampal neurons (Klein et 
al., 2006). The absence of SRP and OSH in our control group is important to address as it may 
obscure statistically significant differences observed in our NR2B KO group. 
On the other hand, confocal fluorescence microscopy indicated that cells within layers 2/3 and 
5, but not layers 4 and 6, in binocular V1 expressed AAV8-CaMKII-Cre-GFP and cells outside of 
V1 also expressed the transgene (Fig. 10). The former observation likely suggests that our 
conditional NR2B knockout was only partially successful, and our findings may be confounded 
by the mosaic genotype of the mice. In other words, our NR2B KO mice may have a significant 
proportion of CaMKII-expressing V1 neurons that retain NR2B function, thereby compensating 
for the small number of NR2B-deficient neurons and obviating any biological effects associated 
with the loss of NR2B. Future iterations of this experiment may more stringently optimize viral 
delivery in order to achieve maximal Cre recombinase activity within V1 neurons, including those 
in layers 4 and 6, which were not appreciably infected in our experiment. For instance, the 
promoter for the murine Six3 gene has been shown to drive the expression of Cre recombinase in 
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layer 4 of cortical tissues (Liao and Xu, 2008).  Furthermore, the high variances accompanying 
our small samples sizes (control: n = 2; NR2B KO: n = 3) may similarly obscure any true biological 
effects of NR2B in potentiating SRP and OSH. Future iterations of this experiment may seek to 
use larger samples within both the NR2B KO and control groups in order to enhance the power of 
the experiment, and also assess other titrations of the viruses to ensure that neither causes non-
specific pathology. Finally, given the age of the mice used in our experiment (p56-66), selective 
deletion of NR2B may not have significant physiological consequences if there are relatively few 
NR2B subunits compared to NR2A subunits; work by Quinlan et al. (1999) suggest that the 
maximal NR2A/NR2B ratio is achieved at or before postnatal 4 weeks. Indeed, experiments using 
genetic ablation of NR2A have reported significant changes in ocular dominance plasticity in mice 
aged p21-34 (Cho et al., 2009; Philpot et al., 2007), which have an average NR2A/NR2B ratio of 
approximately 1 (Quinlan et al., 1999). Future iterations of our experiment here my opt to include 
younger Grin2bfl/fl mice (p21-34 or younger) in order to capture a larger biological effect 
associated with NR2B ablation.  
5.3 High concentration DMSO occludes the acquisition, but not the consolidation, of 
visual memory 
In order to further characterize the function of NR2B in SRP and OSH, we also inhibited NR2B 
using CP-101,606, a selective NR2B antagonist whose precise binding profile has not been fully 
elucidated. Preliminary work indicates that CP-101,606 binds at the interface between NR2B and 
NR1 and interacts with Tyr-109, Gly-112, Ser-132, and Ile-133 on NR1 and Gln-110 on NR2B 
(Fig. 15B) (Burger et al., 2012). CP-101,606 is a structural analog of ifenprodil, a negative 
allosteric modulator of NR2B, and differs by the shorter linker region and additional hydroxyl 
group (Fig. 15D). These differences may contribute to the tighter binding at the NR1/NR2B 
interface and the resulting 2.5-fold higher potency than ifenprodil. IC50 and KD values of CP-
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101,606 inhibition of NR2B-containing NMDA receptor have previously been reported to be 
0.0039 µM (Fig. 15D) and 4.2-12.0 nM in vivo, respectively, suggesting that CP-101,606 is a 



























Figure 15: Ifenprodil, which is structurally similar to Ro 25-6981 and traxoprodil (i.e., CP-
101,606), binds to the GluN1/GluN2B (i.e. NR1/NR2B) interface. (A) Structural representation 
of the NMDA receptor consisting of NR1 and NR2B subunits. ATD, extracellular amino-terminal 
domain; LTD, extracellular ligand-binding domain; TMD, transmembrane domain; CTD, 
intracellular carboxyl-terminal domain. (B) Close-up of the NR1/NR2B binding interface. CP-
101,606 interacts with Tyr-109 (NR1) and Gln-110 (NR2B), as well as Gly-112, Ser-132, and Ile-
133 (NR1) (not shown). Ro 25-6981 interacts with Phe-176 (NR2B), as well as Asp-101 and Thr-
233 (NR2B) (not shown). Cyan represents the hydrophobic aromatic rings; blue depicts the 
hydrogen bond donors; red shows the hydrogen bond acceptors. (C) Depiction of a general 
D 
A B C 
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pharmacophore model for NR2B antagonists, following the same color scheme as (B). (D) 
Molecular structures of ifenprodil, Ro 25-6981, and CP-101,606 and corresponding IC50 values. 
Figure adapted from Burger et al. (2012). 
 
During our initial pilot testing, we encountered issues in dissolving CP-101,606 using reported 
methods including acidified sterile saline (pH 4), serial ethanol dilutions, or low concentration 
DMSO in sterile water (10% v/v), along with sonication). We obtained a stable drug suspension 
with a 10% v/v ethanol and 50% v/v glycerol solution but observed no clear effects upon in vivo 
injection prior to SRP training (data not shown). Thus, we subsequently aimed to use a fully 
solubilized CP-101,606 in a solution of 75% v/v DMSO in sterile water. Interestingly, our 
observations within the vehicle control group suggest that high DMSO concentration alone may 
have an effect on potentiation. Indeed, VEP magnitudes measured post-DMSO treatment were 
higher than those measured prior to DMSO treatment. Moreover, stimuli presented immediately 
after DMSO treatment failed to potentiate VEPs after the initial training (tested on day 3) while 
the stimulus presented immediately before DMSO treatment underwent reliable potentiation 
between days 1 and 3 (Fig. 13). Together these data suggest that DMSO blocks the acquisition, 
but not the consolidation of visual memory. As the same trends were observed in the CP-101,606 
treatment group, we were unable to draw any conclusions about the role of NR2B in SRP and OSH 
(Fig. 13). 
DMSO is an aprotic solvent that is known to disrupt biological membranes thereby permitting 
medical applications, including transdermal drug delivery (Notman et al., 2006). To our 
knowledge, no prior reports have suggested that DMSO has an effect on the potentiation of SRP 
and OSH. Though prior work on measuring excitatory postsynaptic potentials of NMDA receptors 
in rat hippocampi demonstrated that low concentration DMSO (0.1% v/v) alone did not produce 
any biological consequences in vivo relative to Propofol dissolved in 0.1% v/v DMSO (Nagashima 
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et al., 2005), high concentrations DMSO may exhibit neurotoxicity or ocular toxicity,  thereby 
eliminating visual stimulus-specific potentiation.  
Interestingly, following the treatment with DMSO, the ability of control mice to undergo SRP 
was observed again after 3 days (Fig. 13), suggesting that the effects of DMSO were transient and 
cortical activity subsequently recovered. Prior pharmacokinetic characterizations of DMSO in 
human models suggest that the half-life of DMSO is on the order of magnitude of 11-14 hours 
(Swanson, 1985). While this reported elimination half-life may not correlate well with mouse 
physiology, a half-life of 11-14 hours may explain the recovery of VEP potentiation; over 97% of 
DMSO is eliminated after 5.14 half-lives corresponding to 3 days. While our findings here are 
fascinating and unexpected, they need to be validated in order to demonstrate that DMSO does 
have an effect on potentiation. It is worth noting that this potentiation may not be unique to V1 or 
the acquisition of visual memory; other processes in the brain, beyond the scope of this project, 
may need to be carefully examined to determine the biological consequences of high concentration 
DMSO, especially as it concerns medical applications of the drug.  
The maximum tolerable dose of DMSO over 24 hours has been reported to be 14 g/kg in mice, 
while the 24-hour LD50 of DMSO has been found to be 20.1 g/kg (Caujolle et al., 1967). Given 
that even at a dose of 50% v/v, DMSO-induced toxicity, including hemolysis, catatonia, and 
hypothermia can be observed in mice (Caujolle et al., 1967), we recognize that the absence of SRP 
and OSH in our mice may be at least partially attributable to physiological consequences of DMSO 
outside of the brain and eyes. Indeed, new observations from our group have suggested that 
physical discomfort or malaise resulting from DMSO administration may shift attention and visual 
processing activities away from visual stimuli, thereby causing larger VEP magnitudes and 
impairing plasticity (unpublished work).  
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There may also be alternative explanations independent of DMSO for the control mice 
exhibiting increased VEP magnitudes post-vehicle-treatment compared to those pre-vehicle-
treatment. For instance, the act of intraperitoneal injection may lead to increased sympathetic 
nervous system activity (e.g., increased heart rate, increased synaptic firing, pupil dilation), 
thereby affecting visual input processing and potentiating VEP magnitudes. Prior work in the Bear 
Lab, however, casts doubt on this hypothesis. Frenkel et al. (2006) reported the use of 
intraperitoneal CPP injections to inhibit NMDA receptors; saline vehicle injections did not 
potentiate VEPs, suggesting that the act of intraperitoneal injection alone does not affect 
neurophysiology. A second hypothesis is the fact that showing a mouse two stimuli, one after the 
other, may potentiate VEPs elicited when viewing the second distinct stimulus. Recent work by 
other members of our group, however, refute this hypothesis. Cooke et al. (2015) presented mice 
with two novel stimuli on the same day and did not observe statistically significant differences in 
VEP magnitudes between the two novel stimuli. In the absence of other plausible explanations, we 
believe our findings are primarily attributable to the physiological consequences of DMSO.  
5.4 Ro 25-6981 inhibition of NR2B shows that NR2B may not necessary for SRP and 
OSH 
Given the numerous methodological issues encountered during our CP-101,606 experiments, 
we opted to repeat our NR2B inhibition experiment with a second antagonist. Ro 25-6981 is a 
selective NR2B antagonist that has been used to modulate spatial learning in rats (Clark et al., 
2017), and many other forms of learning and plasticity. Biochemically, Ro 25-6981 binds to NR2B 
and interacts specifically with Asp-101, Phe-176, and Thr-233 residues located within a central 
cleft of a leucine, isoleucine, valine periplasmic amino acid-binding protein (LIVBP) binding 
domain found within the amino terminus (Fig. 15B) (Burger et al., 2012; Malherbe et al., 2003). 
Note the structural similarity between Ro 25-6981 and ifenprodil; Ro 25-6981 differs by a chiral 
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center and an additional carbon atom in the linker region. IC50 and KD values of Ro 25-6981 
inhibition of NR2B-containing NMDA receptors have previously been reported to be 0.009 µM 
(Fig. 15D) and 0.003 µM in vitro, respectively, suggesting that Ro 25-6981 is potent inhibitor of 
NR2B (Burger et al., 2012; Fischer et al., 1997; Mutel et al., 1998). 
While the effects previously observed using DMSO vehicle were not observed in the saline-
treated control group here, we did not observe any statistically significant differences in VEP 
magnitudes between mice treated with Ro 25-6981 and those treated with a saline control, 
suggesting that NR2B likely does not play a role in SRP and supporting conclusions drawn from 
our NR2B knockout experiments above. Interestingly, though we saw no apparent effects of Ro 
25-6981 on SRP, we noted that, on average, VEP magnitudes for vehicle-treated mice were 
marginally larger than those observed in Ro 25 6981-treated mice (not statistically significant), 
possibly indicating that NR2B may play a role in response sensitivity to visual stimuli. These 
findings were also observed in NR2B KO mice. 
Though statistically insignificant, we observed a large reduction in potentiation from day 3-7 
in Ro 25-6981-treated mice relative to control mice in response to the post-drug familiar 75˚ 
stimulus (Fig. 14), potentially suggesting an impairment of visual memory acquisition related to 
the administration of Ro 25-6981 48 hours prior. Interestingly, the half-life of dissociation of Ro 
25-6981 in vitro has been reported to be on the order of magnitude of five hours (Mutel et al., 
1998), that direct pharmacological inhibition of NR2B likely does not contribute to our 
observations here. Instead, we hypothesize that the inhibition of NR2B by Ro 25-6981 causes other 
longer-lasting physiologic changes, such as the compensatory expression of NR2B-containing 
NMDA receptors to recover normal synaptic signaling, which may contribute to alterations in SRP 
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and visual memory acquisition. Future experiments are necessary to identify these precise 
physiologic changes and investigate their causal relationship to SRP. 
Cooke et al. (2015) described OSH, which co-occurs with SRP in response to familiar visual 
stimulus. We were unable to conclusively evaluate OSH in any of the experiments described in 
this work since the vidget response is inherently variable. Therefore, differences in vidget 
magnitudes between experimental and control conditions were not statistically significant likely 
due to the small sample sizes. Differences in vidget magnitudes between stimulation conditions 
within the same experimental/control groups were also not statistically significant. Our findings 
reflect a known caveat of OSH, which is not a reliable assay for the acquisition of visual memory 
in small samples. Future iterations of our experimental approach may opt to replicate the OSH 
acquisition protocol described here to obtain much larger sample sizes (e.g., n = 15, as described 
in Cooke et al. (2015)) to better characterize OSH.  
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6 Future directions 
In this volume, we attempted to characterize biochemical changes in NMDA receptor subunit 
composition during the acquisition of visual memory and the role of NR2B in SRP and OSH. We 
have already discussed several methodological changes and avenues for further scientific 
exploration. Importantly, increasing sample size will enhance statistical power, thereby elucidating 
biological phenomenon from variance. Furthermore, including younger cohorts of mice, which 
have lower NR2A/NR2B ratios, may enhance biological effects seen during the inhibition of 
NR2B. Further optimization of vidget acquisition protocols may also improve characterization of 
OSH. 
As one of our incidental observations was a decrease in VEP magnitude in response to Ro 25-
6981 inhibition of NR2B, this NMDA receptor subunit may play a role in regulating VEP 
magnitudes by increasing sensitivity to visual stimuli. We also incidentally observed that stimuli 
presented immediately after DMSO treatment failed to potentiate VEPs, suggesting that DMSO 
may inhibit the acquisition of memory. The involvement of NR2B in SRP and OSH is more 
nebulous, but future experiments may be focused on further characterizing the role of NR2B in 
visual input processing in V1. As one of our alternative explanations for this phenomenon is the 
compensatory overexpression of NR2A and NR1, future experiments should also examine gene 
expression changes in V1 neurons following the loss of NR2B function. Similarly, if the loss of 
NR2B does cause changes in VEP magnitudes by overexpressing NR2A, future experiments can 




In summary, NMDA receptor subunit composition in V1 does not appear to change during the 
acquisition of visual memory in wild-type (p27-29) C57BL/6N mice as determined by the 
measurement of NR2A and NR2B via Western blot. Given that NMDA receptors are necessary 
for SRP and OSH (Cooke et al., 2015; Frenkel et al., 2006), we chose to investigate the role of 
NR2B in these processes. SRP measurements obtained following genetic ablation of NR2B using 
an intersectional transgenic approach could not conclusively determine if NR2B is necessary for 
SRP and OSH due to unexpected effects of the control treatment. These results were further 
clarified by the pharmacological inhibition of NR2B via Ro 25-6981 during training. We observed 
that Ro 25-6981 injected immediately before or after training had no significant impact on SRP or 
OSH. Ro 25-6981, however, may have long-term consequences on further induction of SRP days 
later, which warrants additional testing. Although we were unable to confirm these results using 
selective NR2B antagonist CP-101,606, we determined that the high concentration of DMSO used 
as a drug vehicle may prevent the acquisition of visual memory, but not its consolidation. In this 
work, we have explored aspects of the biochemistry and neurophysiology of NMDA receptor 
subunit NR2B in the context of visual memory, but our findings are by no means a complete 
characterization of the protein’s function in normal biology and the biological processes that 
underlie visual memory. Indeed, our experiments with selective NR2B antagonist Ro 25-6981 may 
suggest that only NR2A-containing NMDA receptors are necessary for SRP. A careful 
examination of the amino acid differences between NR2A and NR2B as well as the biochemical 
properties of the two subunits may help to further elucidate the biochemical basis for SRP. Yet, it 
is important to recognize that as Ro 25-6981 binds to NR2B at the interface between NR2B and 
NR1 (Chazot et al., 2002; Mutel et al., 1998), other areas of NR2B may still be functional and 
contribute to biological processes, including SRP. Ultimately, understanding the function and role 
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of these proteins in visual recognition memory will contribute to a broader appreciation of 
neuroscience and aid in the development of new therapeutics that target these proteins to enhance 
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Figure S1: NR2B and NR2A are upregulated in equal proportion in the frontal cortex with 
increasing visual experience despite no apparent change in total NMDA receptor number. 
(A) The NR2A/NR2B ratio determined via Western Blot of frontal cortical tissue does not differ 
significantly between control mice shown a grey screen for 6 days, control mice shown a 45˚ 
grating stimulus on day 1 and grey screen for the subsequent 5 days, control mice shown a grey 
screen for 5 days and a 45˚ grating stimulus on day 6, and mice shown a 45˚ grating stimulus for 
6 days (n = 5). Values reported were calculated as proportion of ratios observed in grey screen 
control mice. (B) The NR2A/NR1 ratio increases in mice shown some visual stimulus relative to 
mice shown grey screen only. (C) The NR2B/NR1 ratio increases in mice shown some visual 
stimulus relative to mice shown grey screen only.  (D) The NR1/b-actin ratio remains relatively 





Figure S2: NR2B and NR2A are upregulated in equal proportion in the visual cortex with 
increasing visual experience despite no apparent change in total NMDA receptor number. 
(A) The NR2A/NR2B ratio determined via Western Blot of visual cortical tissue does not differ 
significantly between control mice shown a grey screen for 6 days, control mice shown a 45˚ 
grating stimulus on day 1 and grey screen for the subsequent 5 days, control mice shown a grey 
screen for 5 days and a 45˚ grating stimulus on day 6, and mice shown a 45˚ grating stimulus for 
6 days (n = 5). Values reported were calculated as proportion of ratios observed in grey screen 
control mice. (B) The NR2A/NR1 ratio appears to increase in mice shown some visual stimulus 
relative to mice shown grey screen only. (C) The NR2B/NR1 ratio appears to increase in mice 
shown some visual stimulus relative to mice shown grey screen only.  (D) The NR1/b-actin ratio 
appears to remain relatively constant in mice shown a 45˚ grating stimulus for 6 days (SRP) and 
control mice shown a 45˚ stimulus on day 1 and grey screen for the subsequent 5 days, while the 
NR1/b-actin ratio appears to increase in control mice shown a grey screen for 5 days and a 45˚ 
grating stimulus on day 6. 
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